Klotho Neuroscience (KLTO) S-1 30 Jan 25 IPO registration Financial data

Document And Entity Information

Document And Entity Information	9 Months Ended
	Sep. 30, 2024
Document Information Line Items
Entity Central Index Key	0001907223
Document Type	S-1
Entity Registrant Name	KLOTHO NEUROSCIENCES, INC.
Entity Incorporation, State or Country Code	DE
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Amendment Flag	false

Unaudited Consolidated Balance

Unaudited Consolidated Balance Sheets - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
ASSETS
Cash	$ 50,895	$ 2,808	$ 75,872
Prepaid expenses	103,750	3,840	3,667
Total current assets	154,645	6,648	329,539
Intangible assets:
Licenses	2,261,134	2,137,638	2,123,750
Patents	48,420	48,420	86,160
Total assets	2,464,199	2,192,706	2,539,449
Current liabilities:
Accounts payable	271,129	151,259	8,014
Accrued expenses	560,299	2,460	4,742
Notes payable		1,308,270	1,347,518
Total current liabilities	982,428	1,620,989	1,360,274
Warrant liability	21,200
Total liabilities	1,003,628	1,620,989
Commitments and contingencies (Note 10)
STOCKHOLDERS’ EQUITY
Preferred stock, value
Common stock, value	1,986	1,513	104,486
Additional paid-in capital	9,649,659	4,493,881	3,539,003
Common stock to be issued	304,462		751,400
Accumulated deficit	(8,495,536)	(3,923,677)	(3,216,219)
Total stockholders’ equity	1,460,571	571,717	1,179,175
Total liabilities and stockholders’ equity	2,464,199	2,192,706	2,539,449
Current assets:
Cash	50,895	2,808	75,872
Prepaid expenses	103,750	3,840	3,667
Total current assets	154,645	6,648	329,539
Other assets
Total other assets			2,209,910
Related Party
ASSETS
Due from related party			250,000
Current liabilities:
Notes payable to related parties	$ 151,000	159,000
Current assets:
Due from related party			250,000
Previously Reported
ASSETS
Cash		2,808
Prepaid expenses		3,840
Total current assets		6,648
Intangible assets:
Licenses		2,137,638
Patents		48,420
Total assets		2,192,706
Current liabilities:
Accounts payable		151,259
Accrued expenses		2,460
Notes payable		1,332,270
Total current liabilities		1,620,989
Commitments and contingencies (Note 10)
STOCKHOLDERS’ EQUITY
Common stock, value		104,486
Additional paid-in capital		3,539,003
Common stock to be issued		851,400
Accumulated deficit		(3,923,677)
Total stockholders’ equity		571,717	203,259
Total liabilities and stockholders’ equity		2,192,706
Current assets:
Cash		2,808
Prepaid expenses		3,840
Total current assets		6,648
Other assets
Total other assets		2,186,058
Previously Reported | Related Party
ASSETS
Due from related party
Current liabilities:
Notes payable to related parties		135,000
Current assets:
Due from related party
Series B Preferred stock
STOCKHOLDERS’ EQUITY
Preferred stock, value			405
Series B Preferred stock | Previously Reported
STOCKHOLDERS’ EQUITY
Preferred stock, value		405
Series C Preferred stock
STOCKHOLDERS’ EQUITY
Preferred stock, value			$ 100
Series C Preferred stock | Previously Reported
STOCKHOLDERS’ EQUITY
Preferred stock, value		$ 100

Unaudited Consolidated Balanc_2

Unaudited Consolidated Balance Sheets (Parentheticals)	Dec. 31, 2023 $ / shares shares
Preferred stock, par value (in Dollars per share) | $ / shares	$ 0.0001
Preferred stock, shares authorized	100,000,000
Preferred stock, shares issued	0
Preferred stock, shares outstanding	0
Common stock, par value (in Dollars per share) | $ / shares	$ 0.0001
Common stock, shares authorized	1,000,000,000
Common stock, shares issued	15,130,393
Common stock, shares outstanding	15,130,393
Series B Preferred stock
Preferred stock, par value (in Dollars per share) | $ / shares	$ 0.001
Preferred stock, shares authorized	500,000
Series C Preferred stock
Preferred stock, par value (in Dollars per share) | $ / shares	$ 0.0001
Preferred stock, shares authorized	5,000,000
Preferred stock, shares issued	1,000,000
Preferred stock, shares outstanding	1,000,000
Previously Reported
Common stock, par value (in Dollars per share) | $ / shares	$ 0.0001
Common stock, shares authorized	1,500,000,000
Common stock, shares issued	1,044,861,360
Common stock, shares outstanding	1,044,861,360
Previously Reported | Series B Preferred stock
Preferred stock, par value (in Dollars per share) | $ / shares	$ 0.001
Preferred stock, shares authorized	500,000
Preferred stock, shares issued	405,250
Preferred stock, shares outstanding	405,250
Previously Reported | Series C Preferred stock
Preferred stock, par value (in Dollars per share) | $ / shares	$ 0.0001
Preferred stock, shares authorized	5,000,000
Preferred stock, shares issued	1,000,000
Preferred stock, shares outstanding	1,000,000

Unaudited Consolidated Statemen

Unaudited Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Professional fees	$ 865,928	$ 117,770	$ 1,634,790	$ 494,075	$ 600,776	$ 526,007
General and administrative	2,005,004	5,967	2,053,794	26,514	30,546	48,367
Total operating expenses	2,870,932	123,737	3,688,584	520,589	631,322	574,374
Net operating loss	(2,870,932)	(123,737)	(3,688,584)	(520,589)	(631,322)	(574,374)
Other income (expense):
Interest expense	(44,956)	(20,379)	(60,020)	(60,472)	76,214	24,366
Change in fair value of warrant liability	41,022		1,325
Other income (expense)	(84,560)	5	(335,830)	78	(78)	(147)
Total other income (expense)	(88,494)	(20,374)	(394,525)	(60,394)	76,136	24,219
Net loss before income taxes	(2,959,426)	(144,111)	(4,083,109)	(580,983)
Income taxes
Net income (loss)	$ (2,959,426)	$ (144,111)	$ (4,083,109)	$ (580,983)	$ (707,458)	$ (598,593)
Net loss per share: Basic (in Dollars per share)	$ (0.18)	$ (0.01)	$ (0.25)	$ (0.04)	$ 0	$ 0
Net loss per share: Diluted (in Dollars per share)	$ (0.18)	$ (0.01)	$ (0.25)	$ (0.04)	$ 0	$ 0
Weighted average common shares outstanding – basic (in Shares)	16,688,945	15,130,393	16,588,940	15,130,393	1,044,861,360	1,044,861,360
Weighted average common shares outstanding – diluted (in Shares)	16,688,945	15,130,393	16,588,940	15,130,393	1,044,861,360	1,044,861,360

Unaudited Consolidated Statem_2

Unaudited Consolidated Statements of Changes in Stockholders’ Equity - USD ($)	Common Stock Previously Reported	Common Stock Adjusted balance		Common Stock Previously Reported	Common Stock	Preferred Stock (Series B, C and D) Previously Reported	Preferred Stock (Series B, C and D) Adjusted balance	Preferred Stock (Series B, C and D) Previously Reported	Preferred Stock (Series B, C and D)	Additional Paid-In Capital Previously Reported	Additional Paid-In Capital Adjusted balance		Additional Paid-In Capital Previously Reported	Additional Paid-In Capital	Common Stock to be Issued Previously Reported	Common Stock to be Issued Adjusted balance		Common Stock to be Issued Previously Reported	Common Stock to be Issued	Accumulated Deficit Previously Reported	Accumulated Deficit Adjusted balance		Accumulated Deficit Previously Reported	Accumulated Deficit	Preferred Stock Series B Previously Reported	Preferred Stock Series B	Preferred Stock Series C Previously Reported	Preferred Stock Series C	Accumulated Deficit During Development Stage Previously Reported	Accumulated Deficit During Development Stage	Previously Reported	Adjusted balance		Previously Reported	Total
Balance at Dec. 31, 2021					$ 104,486									$ 3,539,003										$ (2,617,626)		$ 405		$ 100							$ 1,026,368
Balance (in Shares) at Dec. 31, 2021					1,044,861,360																					405,250		1,000,000
Stock subscription/compensation - common stock																			751,400																751,400
Net income (loss)																								(598,593)											(598,593)
Balance at Dec. 31, 2022		$ 1,513			$ 104,486			$ 475			$ 4,493,881		$ 3,419,003	3,539,003					751,400		$ (3,216,219)		$ (3,216,219)	(3,216,219)		$ 405		$ 100				$ 1,279,175		$ 203,259	1,179,175
Balance (in Shares) at Dec. 31, 2022		15,130,393			1,044,861,360			1,405,250																		405,250		1,000,000
Retroactive application of merger				$ 1,513				$ (475)					1,074,878																					1,075,916
Retroactive application of merger (in Shares)				15,130,393				(1,405,250)
Net income (loss)																					(580,983)											(580,983)			(580,983)
Balance at Sep. 30, 2023		$ 1,513									4,493,881										(3,797,202)											698,192
Balance (in Shares) at Sep. 30, 2023		15,130,393
Balance at Dec. 31, 2022		$ 1,513			$ 104,486			$ 475			4,493,881		3,419,003	3,539,003					751,400		(3,216,219)		(3,216,219)	(3,216,219)		$ 405		$ 100				1,279,175		203,259	1,179,175
Balance (in Shares) at Dec. 31, 2022		15,130,393			1,044,861,360			1,405,250																		405,250		1,000,000
Stock subscription & license purchase																			100,000																100,000
Net income (loss)																								(707,458)											(707,458)
Balance at Dec. 31, 2023	$ 1,513	$ 1,568	[1]	$ 104,486	$ 1,513	$ 12				$ 4,493,881	3,175,209	[1]	3,539,003	4,493,881		$ 304,200	[1]	$ 851,400		$ (3,923,677)	(3,923,677)	[1]	(3,923,677)	(3,923,677)	$ 405		$ 100				$ 571,729	(442,700)	[1]	571,717	571,717
Balance (in Shares) at Dec. 31, 2023	15,130,393	15,678,898	[1]	1,044,861,360	15,130,393	120,000																			405,250		1,000,000
Balance at Sep. 30, 2023		$ 1,513									4,493,881										(3,797,202)											698,192
Balance (in Shares) at Sep. 30, 2023		15,130,393
Net income (loss)																								(126,475)											(126,475)
Balance at Dec. 31, 2023	$ 1,513	$ 1,568	[1]	$ 104,486	$ 1,513	$ 12				4,493,881	3,175,209	[1]	3,539,003	4,493,881		304,200	[1]	851,400		(3,923,677)	(3,923,677)	[1]	(3,923,677)	(3,923,677)	$ 405		$ 100				571,729	(442,700)	[1]	571,717	571,717
Balance (in Shares) at Dec. 31, 2023	15,130,393	15,678,898	[1]	1,044,861,360	15,130,393	120,000																			405,250		1,000,000
Retroactive application of merger	$ 55					$ (12)				(1,318,672)					304,200																(1,014,429)
Retroactive application of merger (in Shares)	548,505					(120,000)
Public warrants assumed from SPAC											488,750										(488,750)
Private warrants assumed from SPAC											(22,525)																					(22,525)
Share-based compensation											37,252					262																37,514
Net income (loss)																					(1,123,683)											(1,123,683)
Balance at Jun. 30, 2024		$ 1,568									3,678,686					304,462					(5,536,110)											(1,551,394)
Balance (in Shares) at Jun. 30, 2024		15,678,898
Balance at Dec. 31, 2023	$ 1,513	$ 1,568	[1]	$ 104,486	$ 1,513	$ 12				$ 4,493,881	3,175,209	[1]	$ 3,539,003	4,493,881		304,200	[1]	$ 851,400		$ (3,923,677)	(3,923,677)	[1]	$ (3,923,677)	(3,923,677)	$ 405		$ 100				$ 571,729	(442,700)	[1]	$ 571,717	571,717
Balance (in Shares) at Dec. 31, 2023	15,130,393	15,678,898	[1]	1,044,861,360	15,130,393	120,000																			405,250		1,000,000
Net income (loss)																																			(4,083,109)
Balance at Sep. 30, 2024					$ 1,986									9,649,659					304,462					(8,495,536)											1,460,571
Balance (in Shares) at Sep. 30, 2024					19,863,515
Balance at Jun. 30, 2024		$ 1,568									$ 3,678,686					$ 304,462					$ (5,536,110)											$ (1,551,394)
Balance (in Shares) at Jun. 30, 2024		15,678,898
Conversion of Notes Payable					$ 375									4,009,634																					4,010,009
Conversion of Notes Payable (in Shares)					3,750,617
Warrant conversion					$ 13																														13
Warrant conversion (in Shares)					130,000
Other														8,518																					8,518
Share-based compensation					$ 30									1,952,821																					1,952,851
Share-based compensation (in Shares)					304,000
Net income (loss)																								(2,959,426)											(2,959,426)
Balance at Sep. 30, 2024					$ 1,986									$ 9,649,659					$ 304,462					$ (8,495,536)											$ 1,460,571
Balance (in Shares) at Sep. 30, 2024					19,863,515
[1] Note: as a result of the business combination as recast, the shares of the Company’s common stock prior to the Business Combination (refer to Note 1) have been retrospectively recast to reflect the change in the capital structure as a result of the Business Combination on 6/21/24.

Unaudited Consolidated Statem_3

Unaudited Consolidated Statements of Cash Flows - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (4,083,109)	$ (580,983)	$ (707,458)	$ (598,593)
Adjustments to reconcile net loss to net cash used in operating activities:
Changes in fair value of warrant liability	(1,325)
Commitment fee	250,000
Stock-based compensation	1,990,366	100,000		1,400
Changes in operating assets and liabilities:
Prepaid expenses	(99,910)	(1,613)	(173)	(7,122)
Accounts payable	19,870	168,966	103,997	4,742
Accrued expenses	557,839	21,224	(2,282)
Tax payable	(568,111)
Related party payable	(128,000)	45,000	135,000
Other liabilities	60,022
Net cash used in operating activities	(2,002,358)	(247,406)	(470,916)	(599,573)
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of patents		(10,000)	37,740	(86,160)
Acquisition of licenses	(123,497)	(66,325)	(13,888)	(39,248)
Net cash used in investing activities	(123,497)	(76,325)	23,852	(125,408)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from convertible promissory note	1,000,000
Proceeds from sales of stocks and warrants, net	175,000
Proceeds from related party loans	100,000
Proceeds from shareholders	120,000
Merger proceeds net of transaction cost	778,942
Proceeds from stock subscriptions			100,000	750,000
Repayment of advance to shareholder		250,000	250,000	(250,000)
Proceeds from notes payable - current portion			24,000
Net cash provided by financing activities	2,173,942	250,000	374,000	500,000
NET CHANGE IN CASH	48,087	(73,731)	(73,064)	(224,981)
Cash - Beginning of period	2,808	75,872	75,872	300,853
Cash - End of period	50,895	2,141	2,808	75,872
SUPPLEMENTAL NON-CASH FINANCING AND INVESTING ACTIVITIES:
Note payable settled with issuance of common stock	5,258,270
Interest payable settled with issuance of common stock	60,022
Non-cash directors and officers insurance	154,500
Non-cash PIPE Funds used for merger transaction close	2,950,000
Commitment fee paid in stock	250,000
Assumed warrant liability from merger	22,525
Assumed income tax payable	568,111
Warrant conversion	96,200
SUPPLEMENTAL CASH FLOW INFORMATION:
Interest Paid	2,460	37,707	78,496	19,624
Taxes Paid
Supplemental disclosure for non-cash financing activities:
Acquisition of drugs licenses with a promissory note (See Note 5)				$ 1,347,518

Organization and Business Descr

Organization and Business Description	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Organization and Business Description [Abstract]
ORGANIZATION AND BUSINESS DESCRIPTION	NOTE 1 — ORGANIZATION AND BUSINESS DESCRIPTION Klotho Neurosciences, Inc. (“The Company” or “Klotho”), formerly known as ANEW Medical, Inc., develops essential medicines for the treatment of chronic diseases – cancer, cardiovascular, and neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and two proprietary, patented technologies involving the melanocortin receptor-binding molecules and a gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called “Klotho” inside the body to treat neurodegenerative diseases. On September 12, 2022, the Company acquired five market-approved anti-cancer drugs approved for sale in Germany. The Market Authorizations (MA’s) are for four of the drugs that comprise the “FOLFOX” and “FOLFIRI” multi-drug regimens used in treatment of metastatic colorectal and gastric cancer and in two of the drugs that are used to treat metastatic lung cancer. The drugs are important in the treatment of many solid tumors in both childhood and adult cancers. Previously, the Company acquired two off-patent bio generic antibodies from Reliance Life Sciences (RLS), the life science arm of Reliance Industries Pvt Ltd. of Navi Mumbai, India. During January 2023, the Company acquired a treatment for small drug molecules that bind to the melanocortin receptors on human cells and affect skin pigmentation. Effective July 24, 2024, the Company changed its legal name from ANEW Medical, Inc. to Klotho Neurosciences, Inc. This name change was approved by the Company’s Board of Directors to better reflect the strategic focus of its proprietary products. Throughout these financial statements, references to the “Company” refer to Klotho Neurosciences, Inc., formerly known as ANEW. Under certain circumstances, references to ANEW have remained when useful in describing the sequence of events that occurred during the merger between Redwoods and ANEW. Business Combinations As of May 30, 2023, Redwoods Acquisition Corp., a Delaware corporation and a special purpose acquisition company (“Redwoods”), Anew Medical Sub, Inc., a Wyoming corporation (“Merger Sub”) and ANEW Medical, Inc., a Wyoming corporation (“ANEW”) entered into a Business Combination Agreement, which was amended as of November 4, 2023 (the “Business Combination Agreement”). On June 21, 2024 (the “Closing Date”), Merger Sub merged with and into ANEW, with ANEW continuing as the surviving corporation and as a wholly owned subsidiary of Redwoods (the “Business Combination”). In connection with the Business Combination, on June 21, 2024, Redwoods filed its Second Amended Certificate of Incorporation with the Delaware Secretary of State, and adopted the amended and restated bylaws (the “Amended and Restated Bylaws”), which replaced Redwoods’ Charter and Bylaws in effect as of such time. In connection with the closing of the Business Combination (the “Closing”), Redwoods changed its name to “ANEW Medical, Inc.” For accounting purposes, the transactions contemplated by the Business Combination are treated as a reverse acquisition and, as such, the historical financial statements of the accounting acquirer ANEW (Wyoming) will become the historical financial statements of the Company. Under this method of accounting, Redwoods was treated as the acquired company for financial reporting purposes. Accordingly, for accounting purposes, the Merger was treated as the equivalent of the Company issuing shares for the net assets of Redwoods, accompanied by a recapitalization. The net assets of Redwoods were stated at historical cost with no goodwill or other intangible assets recorded. Recapitalization In connection with the merger, the Company issued six million shares in exchange for all of the outstanding shares of ANEW. At $10 per Redwood’s share, the valuation of ANEW was $60 million. Immediately after giving effect to the Business Combination, 15,130,393 shares of Company Common Stock were outstanding, from which 2,875,000 remain in escrow for the Redwoods founders. In addition, there were 12,030,000 warrants immediately exercisable and composed of 11,500,000 public warrants and 530,000 private warrants. Following the Closing, on June 21, 2024, the Company’s Common Stock and Warrants began trading on the Nasdaq under the symbols “WENA” and “WENAW,” respectively. The Public Units of Redwoods automatically separated into the component securities upon consummation of the Business Combination and, as a result, no longer trade as a separate security. Further, upon closing of the Business Combination on June 21, 2024, the Company received approximately $181,339 in net cash proceeds. During the three months ended September 30, 2024, the Company determined there was an additional approximate $8,500 cash. At Closing, pursuant to the terms of the Business Combination Agreement and after giving effect to the redemptions of shares of Redwoods Common Stock: ● The total consideration paid at Closing (the “Merger Consideration”) by Redwoods to ANEW Medical, Inc. security holders was 6,000,000 shares of the Company common stock valued at $60 million (the “Consideration Shares”), based on an implied ANEW equity value of $60,000,000 valued at $10 per share; ● Each share of ANEW Medical Common Stock, if any, that was owned by Redwoods, Merger Sub, ANEW Medical, Inc. or any other affiliate of Redwoods immediately prior to the effective time of the Merger (the “Effective Time”) was automatically cancelled and retired without any conversion or consideration; ● Each share of Merger Sub common stock, par value $0.0001 per share (“Merger Sub Common Stock”), issued and outstanding immediately prior to the Effective Time was converted into one newly issued share of Common Stock of the Surviving Corporation. In connection with the Merger, the Company entered into a convertible promissory note and Securities Purchase Agreement (“SPA”) with certain accredited investors (the “Redwoods PIPE Investors”) for an aggregate of 750,000 shares (bonus free trading shares and restricted shares issued at closing), with each unit consisting of one share of Company common stock (the “PIPE Shares”) for an aggregate purchase price of $2,000,000 (the “Redwoods PIPE Financing”). Upon the closing of the Redwoods PIPE Financing (which closed in connection with the closing of the Merger), the $2,000,000 were used by the Company to settle transaction costs. The Company received approximately $181,339 in net cash proceeds and recorded a receivable of $50,000 from the Redwoods PIPE Financing funds. In connection with the Merger, the Company entered convertible promissory note and Securities Purchase Agreement (“SPA”) with certain accredited investors (the “ANEW PIPE Investors”) for an aggregate of 854,257 units (bonus free trading shares and restricted shares issued at closing), with each unit consisting of one share of Company common stock (the “PIPE Shares”) for an aggregate purchase price of $2,000,000 (the “ANEW PIPE Financing”). Upon the closing of the ANEW PIPE Financing (which closed in connection with the closing of the Merger), $1,000,000 was used by the Company to settle transaction costs. The Company received approximately $950,000 in cash proceeds and recorded a receivable of $50,000 from the ANEW PIPE Financing funds. Concurrent with Closing, certain ANEW stockholders may be entitled to up to an additional 5,000,000 shares of Company Common Stock (the “ Contingent Consideration Shares (i) 2,000,000 Contingent Consideration Shares upon the Company’s common stock achieving a closing price equal to or exceeding $12.50 for 10 trading days within a 20-day trading period in the first three years following the Closing; (ii) 2,000,000 Contingent Consideration Shares upon the Company’s common stock achieving a closing price equal to or exceeding $15.00 for 10 trading days within a 20-day trading period in the first three years following the Closing; and (iii) 1,000,000 Contingent Consideration Shares upon the Company’s common stock achieving a closing price equal to or exceeding $20.00 for 10 trading days within a 20-day trading period in the first five years following the Closing. In accordance with guidance applicable to these circumstances, the equity structure has been restated in all comparable periods up to June 21, 2024 and reflected as such as of September 30, 2024, to reflect the number of shares of the Company’s common stock, $0.0001 par value per share, issued to ANEW’s stockholders in connection with the merger. As such, the shares and corresponding capital amounts and earnings per share related to ANEW’s common stock prior to the merger have been retroactively restated as shares reflecting the exchange ratio established in the merger. For accounting purposes, the Merger was treated as the equivalent of the Company issuing shares for the net assets of Redwoods, accompanied by a recapitalization. The net assets of Redwoods were stated at historical cost with no goodwill or other intangible assets recorded. In connection with the Merger, in addition to the warrants, ANEW Medical assumed $589,081 in cash and $568,111 in income tax payable. The income tax payable of $568,111 was settled in full as of September 30, 2024 from the assumed $589,081 cash.	NOTE 1 – ORGANIZATION AND BUSINESS DESCRIPTION Klotho Neurosciences, Inc. (“The Company” or “Klotho”), formerly known as ANEW Medical, Inc., develops essential medicines for the treatment of chronic diseases – cancer, cardiovascular, and neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and two proprietary, patented technologies involving the melanocortin receptor-binding molecules and a gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called “Klotho” inside the body to treat neurodegenerative diseases. On September 12, 2022, the Company acquired five market-approved anti-cancer drugs approved for sale in Germany. The Market Authorizations (MA’s) are for four of the drugs that comprise the “FOLFOX” and “FOLFIRI” multi-drug regimens used in treatment of metastatic colorectal and gastric cancer and in two of the drugs that are used to treat metastatic lung cancer. The drugs are important in the treatment of many solid tumors in both childhood and adult cancers. Previously, the Company acquired two off-patent bio generic antibodies from Reliance Life Sciences (RLS), the life science arm of Reliance Industries Pvt Ltd. of Navi Mumbai, India. During January 2023, the Company acquired a treatment for small drug molecules that bind to the melanocortin receptors on human cells and affect skin pigmentation. As of May 30, 2023, Redwoods Acquisition Corp., a Delaware corporation and a special purpose acquisition company (“Redwoods”), Anew Medical Sub, Inc., a Wyoming corporation (“Merger Sub”) and ANEW Medical, Inc., a Wyoming corporation (“ANEW”) entered into a Business Combination Agreement, which was amended as of November 4, 2023 (the “Business Combination Agreement”).

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Summary of Significant Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Going Concern The accompanying unaudited consolidated financial statements have been prepared as if the Company will continue as a going concern. The Company has incurred significant operating losses and negative cash flows from operations since inception. As of September 30, 2024, the Company had cash of approximately $51,000 and an accumulated deficit of approximately $8.5 million. The Company has incurred recurring losses, has experienced recurring negative operating cash flows, and requires significant cash resources to execute its business plans. The Company is dependent on obtaining additional working capital funding from the sale of equity and/or debt securities in order to continue to execute its development plans and continue operations. Without additional funding, there is substantial doubt about the Company’s ability to continue as a going concern for twelve months from the date of these financial statements. Basis of Presentation and Principles of Consolidation The Company prepares its consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC. The Company prepared the Financial Statements, without audit, pursuant to the rules and regulations of the SEC applicable to quarterly reporting on Form 10-Q and reflect, in management’s opinion, all adjustments necessary to present fairly the financial information. All such adjustments are of a normal recurring nature. Certain information and footnote disclosures normally included in financial statements, prepared in accordance with generally accepted accounting principles, have been consolidated or omitted as permitted by such rules and regulations. These Financial Statements should be read in conjunction with the consolidated financial statements and related notes included in the 2023 Annual Report. Results of operations for interim periods are not necessarily indicative of annual results. Reclassification Certain prior year amounts have been reclassified for comparative purposes to conform to the current-year financial statement presentation. These reclassifications had no effect on previously reported results of operations and were not material. Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Use of Estimates The preparation of unaudited consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. Cash and Cash Equivalents Cash and cash equivalents represent cash on hand, demand deposits, and other short-term highly liquid investments placed with banks, which have original maturities of three months or less and are readily convertible to known amounts of cash. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. As of September 30, 2024, the Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. Fair Value of Financial Instruments The assets and liabilities are valued using a fair market basis as defined in the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) ASC 820, Fair Value Measurement. Fair value is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date. The Company uses a three-level hierarchy established by the FASB that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach and cost approach). The levels of the fair value hierarchy are described below: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs with little or no market data available, which require the reporting entity to develop its own assumptions. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. Financial assets and liabilities are classified in their entirety based on the most conservative level of input that is significant to the fair value measurement. Fair value measurements at reporting date using: Fair value Quoted prices in active markets for identical liabilities (Level 1) Significant other Significant unobservable inputs Liabilities: Representative warrant liabilities, September 30, 2024 $ 21,200 $ - $ - $ 21,200 Liabilities: Representative warrant liabilities, December 31, 2023 $ - $ - $ - $ - The following tables present a reconciliation of the Level 3 Private Warrants liabilities: Nine Months Ended 2024 2023 Representative warrant liabilities, January 1 $ - $ - Issuances/Assumptions 22,525 - Change in fair value (1,325 ) - Representative warrant liabilities, September 30 $ 21,200 $ - Three Months Ended 2024 2023 Representative warrant liabilities, July 1 $ 62,222 $ - Change in fair value (41,022 ) - Representative warrant liabilities, September 30 $ 21,200 $ - Intangible Assets The Company’s intangible assets consist of acquired medical licenses and patents. The Company acquires medical licenses for the treatment of medical conditions to market and sell in the future. The initial asset cost is the cost to acquire the license. Once in use, the Company amortizes the license cost over the useful life using the straight-line method. As part of the licensing agreements, the Company acquires patents and records the cost to acquire patents as the initial asset cost. Once the patents are approved and in use, assuming no litigations expenses, the Company amortizes the patent cost over the useful life using the straight-line method. The amortization period will not exceed the lifespan of the protection afforded by the patent. If the expected useful life of the patent is even shorter, the Company will use the useful life for amortization purposes. Thus, the shorter of a patent’s useful life or legal life will be used for the amortization period. Impairment of Long-Lived and Intangible Assets The Company assesses the impairment of long-lived and intangible assets periodically, or at least annually, and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors considered important, which could trigger an impairment review, include the following: significant underperformance relative to historical or projected future cash flows; significant changes in the manner of use of the assets or the strategy of the overall business; and significant negative industry trends. When management determines that the carrying value of long-lived and intangible assets may not be recoverable, impairment is measured as the excess of the assets’ carrying value over the estimated fair value. Management is not aware of any other impairment charges that may currently be required; however, the Company cannot predict the occurrence of events that might adversely affect the reported values in the future. On an annual basis, the Company tests the long-lived and intangible assets for impairment based on the projected net present value of cash flows for each asset. Prior to the annual impairment test, if circumstances change and a long-lived or intangible asset is deemed impaired, an impairment loss will be immediately recognized in the statements of operations. At December 31, 2023, the date of the last impairment test, it was determined that the estimated fair value of the intangible assets exceeded the carrying value of the assets by 50%, indicating no impairment. Revenue Recognition The Company is in a pre-revenue state and does not generate revenue. When the Company commences to derive revenue, those contracts will be accounted in accordance with ASU 2014-09, Revenue from Contracts with Customers (Topic ASC 606). Income Taxes The Company uses the asset and liability method of accounting for income taxes in accordance with ASU 740, “Income Taxes”. Under this method, income tax expense is recognized as the amount of: (i) taxes payable or refundable for the current year and (ii) future tax consequences attributable to differences between the consolidated financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of available evidence it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company is subject to Income tax filings requirements in U.S. federal and various state jurisdictions. The Company’s tax returns for years from 2021, 2022, and 2023 are subject to U.S. federal, state, and local income tax examinations by tax authorities. The Company reports income tax related interest and penalties within the income tax line item on the consolidated statements of operations. The Company likewise reports the reversal of income tax-related interest and penalties within such line item to the extent the Company resolves the liabilities for uncertain tax positions in a manner favorable to the accruals. Net Loss Per Share (Basic and Diluted) Basic net loss per share is computed by dividing net loss by the weighted average number of shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares outstanding, plus the number of additional shares that would have been outstanding if the common share equivalents had been issued, if dilutive. The following table details the net loss per share calculation, reconciles between basic and diluted weighted average shares outstanding, and presents the potentially dilutive shares that are excluded from the calculation of the weighted average diluted common shares outstanding, because their inclusion would have been anti-dilutive: For the Nine Months Ended 2024 2023 Numerator: Net loss $ (4,083,109 ) $ (580,983 ) Weighted average shares outstanding (denominator for basic earnings per share) 16,588,940 15,130,393 Weighted average shares and assumed potential common shares (denominator for diluted earnings per share, treasury method) 16,588,940 15,130,393 Basic loss per share $ (0.25 ) $ (0.04 ) Diluted loss per share $ (0.25 ) $ (0.04 ) The following common share equivalents are excluded from the calculation of weighted average common shares outstanding, because their inclusion would have been anti-dilutive: For the Nine Months Ended 2024 2023 Warrants 12,030,000 12,030,000 Total potentially dilutive shares 12,030,000 12,030,000 Research and Development Cost Research and development (R&D) costs are expensed as incurred. R&D costs are related to the Company’s internally funded development of the Company medical licenses and patents. The Company R&D costs were $0 for the three and nine months ended September 30, 2024 and 2023, respectively. Share-based Compensation The Company accounts for share-based compensation in accordance with the fair value recognition provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) No. 718 and No. 505. The Company issues restricted stock to employees and consultants for their services. Cost for these transactions are measured at the fair value of the equity instruments issued at the date of grant. These shares are considered fully vested and the fair market value is recognized as an expense in the period granted. The Company recognized consulting expenses and a corresponding increase to additional paid-in-capital related to stock issued for services. For agreements requiring future services, the consulting expense is to be recognized ratably over the requisite service period. The Company recorded share-based compensation of $1,990,366 and $100,000 for the nine months ended September 30, 2024, and 2023, respectively. Warrants As of September 30, 2024, the fair value of the Representative Warrant liabilities was $21,200 based on the closing price of the warrants on The Nasdaq Capital Market. The fair value of the Representative Warrants was approximately $0.04 per Representative Warrant, which was based on the relative fair value to the Public Warrants. During the quarter, our Public and Private Warrants met the conditions necessary to adjust the exercise price and the redemption trigger price. As of September 30, 2024, the exercise price was $3.49 per warrant, and the redemption trigger price was $5.01. During the three months ended September 30, 2024, the fair value of the Representative warrants decreased by $41,022. During the three months ended September 30, 2024, a warrant holder exercised 130,000 warrants issued as part of the Series D Preferred Shares related to the Business Combination, with a total value of $96,200, valued as of September 27, 2024. Related Parties The Company follows subtopic 850-10 of the FASB Accounting Standards Codification for the identification of related parties and disclosure of related party transactions. Pursuant to Section 850-10-20 the related parties include (a) affiliates of the Company; (b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; (c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; (d) principal owners of the Company; (e) management of the Company; (f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and (g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests. The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: (a) the nature of the relationship(s) involved; (b) description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; (c) the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and (d) amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement. Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s consolidated financial statements.	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Going Concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred material recurring losses from operations. The Company has not generated material revenues since inception and has generated losses totaling $3,923,677 since inception. The consolidated financial statements do not contain any adjustments to reflect the possible future effects on the classification of assets or the amounts and classification of liability that may result should the Company be unable to continue as a going concern. Basis of Presentation and Principles of Consolidation The Company prepares its consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC. The Company prepared the Financial Statements pursuant to the rules and regulations of the SEC and reflect, in management’s opinion, all adjustments necessary to present fairly the financial information. All such adjustments are of a normal recurring nature. Certain information and footnote disclosures normally included in financial statements, prepared in accordance with generally accepted accounting principles, have been consolidated or omitted as permitted by such rules and regulations. Reclassification Certain prior year amounts have been reclassified for comparative purposes to conform to the current-year financial statement presentation. These reclassifications had no effect on previously reported results of operations and were not material. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires the Company to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and the accompanying notes. Such estimates include life of intangible assets, accrued liabilities, income taxes, long-lived assets, and deferred tax valuation allowances. These estimates generally involve complex issues and require management to make judgments, involve analysis of historical and future trends that can require extended periods of time to resolve, and are subject to change from period to period. In all cases, actual results could differ materially from estimates. Cash and Cash Equivalents Cash and cash equivalents represent cash on hand, demand deposits, and other short-term highly liquid investments placed with banks, which have original maturities of three months or less and are readily convertible to known amounts of cash. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company did not hold cash in excess of FDIC insurance coverage at a financial institution as of December 31, 2023 and 2022. Fair Value of Financial Instruments The assets and liabilities are valued using a fair market basis as defined in the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) ASC 820, Fair Value Measurement. Fair value is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date. The Company uses a three-level hierarchy established by the FASB that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach and cost approach). The levels of the fair value hierarchy are described below: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs with little or no market data available, which require the reporting entity to develop its own assumptions. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. Financial assets and liabilities are classified in their entirety based on the most conservative level of input that is significant to the fair value measurement. The Company did not identify any assets or liabilities that are required to be adjusted on the balance sheet to fair value as of December 31, 2023 and 2022. Intangible Assets The Company’s intangible assets consist of acquired medical licenses and patents. The Company acquires medical licenses for the treatment of medical conditions to market and sell in the future. The initial asset cost is the cost to acquire the license. Once in use, the Company amortizes the license cost over the useful life using the straight-line method. As part of the licensing agreements, the Company acquires patents and records the cost to acquire patents as the initial asset cost. Once the patents are approved and in use, assuming no litigations expenses, the Company amortizes the patent cost over the useful life using the straight-line method. The amortization period will not exceed the lifespan of the protection afforded by the patent. If the expected useful life of the patent is even shorter, the Company will use the useful life for amortization purposes. Thus, the shorter of a patent’s useful life or legal life will be used for the amortization period. Impairment of Long-Lived and Intangible Assets The Company assesses the impairment of long-lived and intangible assets periodically, or at least annually, and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors considered important, which could trigger an impairment review, include the following: significant underperformance relative to historical or projected future cash flows; significant changes in the manner of use of the assets or the strategy of the overall business; and significant negative industry trends. When management determines that the carrying value of long-lived and intangible assets may not be recoverable, impairment is measured as the excess of the assets’ carrying value over the estimated fair value. Management is not aware of any other impairment charges that may currently be required; however, the Company cannot predict the occurrence of events that might adversely affect the reported values in the future. On an annual basis, the Company tests the long-lived and intangible assets for impairment based on the projected net present value of cash flows for each asset. Prior to the annual impairment test, if circumstances change and a long-lived or intangible asset is deemed impaired, an impairment loss will be immediately recognized in the statements of operations. At December 31, 2023, the date of the last impairment test, it was determined that the estimated fair value of the intangible assets exceeded the carrying value of the assets by 50%, indicating no impairment. Revenue Recognition The Company is in a pre-revenue state and does not generate revenue. When the Company commences to derive revenue, those contracts will be accounted in accordance with ASU 2014-09, Revenue from Contracts with Customers (Topic ASC 606). Income Taxes The Company uses the asset and liability method of accounting for income taxes in accordance with ASU 740, “Income Taxes”. Under this method, income tax expense is recognized as the amount of: (i) taxes payable or refundable for the current year and (ii) future tax consequences attributable to differences between the consolidated financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of available evidence it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company is subject to Income tax filings requirements in U.S. federal and various state jurisdictions. The Company’s tax returns for years from 2021, 2022, and 2023 are subject to U.S. federal, state, and local income tax examinations by tax authorities. The Company reports income tax related interest and penalties within the income tax line item on the consolidated statements of operations. The Company likewise reports the reversal of income tax-related interest and penalties within such line item to the extent the Company resolves the liabilities for uncertain tax positions in a manner favorable to the accruals. Net Loss Per Share (Basic and Diluted) Basic net loss per common share is computed using the weighted average number of common shares outstanding. Diluted earnings per share (EPS) include additional dilution from common stock equivalents, such as stock issuable pursuant to convertible notes. Common stock equivalents are not included in the computation of diluted earnings per share when the Company reports a loss because to do so would be anti-dilutive for the periods presented. On December 31, 2023 the Company’s common stock equivalents consisted of 405,250 shares of Series B preferred stock outstanding which may be converted into 40,525,000 shares of the Company’s common stock and 851,400 shares common stock to be issued for an aggregate of 41,376,400 shares of common stock. Research and Development Cost Research and development (R&D) costs are expensed as incurred. R&D costs are related to the Company’s internally funded development of the Company medical licenses and patents. The Company had R&D costs were $-0- for the years ended December 31, 2023 and 2022, respectively. Share-based Compensation The Company accounts for share-based compensation in accordance with the fair value recognition provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) No. 718 and No. 505. The Company issues restricted stock to employees and consultants for their services. Cost for these transactions are measured at the fair value of the equity instruments issued at the date of grant. These shares are considered fully vested and the fair market value is recognized as an expense in the period granted. The Company recognized consulting expenses and a corresponding increase to additional paid-in-capital related to stock issued for services. For agreements requiring future services, the consulting expense is to be recognized ratably over the requisite service period. The Company recorded share-based compensation of $-0- Related Parties The Company follows subtopic 850-10 of the FASB Accounting Standards Codification for the identification of related parties and disclosure of related party transactions. Pursuant to Section 850-10-20 the related parties include (a) affiliates of the Company; (b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; (c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; (d) principal owners of the Company; (e) management of the Company; (f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and (g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests. The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: (a) the nature of the relationship(s) involved; (b) description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; (c) the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and (d) amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement. Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s consolidated financial statements. Prepaid Expenses The Company considers all items incurred for future services to be prepaid expenses. The prepaid expenses were $3,840 and $3,667 at December 31, 2023 and 2022, consisting of the OTC Market annual fee. Property and equipment Property and equipment are recorded at cost and depreciated on the straight-line method over the estimated useful lives. Expenditures for normal repairs and maintenance are charged to expense as incurred. The cost and related accumulated depreciation of assets sold or otherwise disposed of are removed from the accounts, and any gain or loss is included in operations. Licenses The Company acquires medical licenses for the treatment of medical conditions to market and sell in the future. The initial asset cost is the cost to acquire the license. Once in use, the Company amortizes the license cost over the useful life using the straight-line method.

Prepaid Expenses

Prepaid Expenses	9 Months Ended
	Sep. 30, 2024
Prepaid Expenses [Abstract]
PREPAID EXPENSES	NOTE 3 — PREPAID EXPENSES Prepaid expenses consist of prepayment of the premium on Directors and Officers insurance. As of September 30, 2024 and December 31, 2023, prepaid expenses totaled $103,750 and $3,840, respectively, in the accompanying consolidated balance sheets.

Intangible Assets

Intangible Assets	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Intangible Assets [Abstract]
INTANGIBLE ASSETS	NOTE 4 — INTANGIBLE ASSETS Intangible assets consisted of the following: Intangible Assets September 30, December 31, Licenses Non-Exclusive License Agreement $ 179,821 $ 56,325 Proprietary pharmaceutical drugs 10,000 10,000 Various generic drugs 736,983 736,983 Four generic drugs (Encore) 1,308,270 1,308,270 Needleless Syringe License 26,060 26,060 Patents 48,420 48,420 Total intangible assets $ 2,309,554 $ 2,186,058 Intangible assets are as follows: ● Non-Exclusive License Agreement ($179,821) st ● Proprietary Pharmaceutical Drugs ($10,000) ment on January 27, 2024. The Company will pay for all new patent costs for new discoveries and new treatments. The Company will make standard commercial development-based milestone payments for the various stages of license development and regulatory approval. In addition, the Company will make royalty payments on the net sales for commercial products. Beginning in 2025, the Company will also pay patent and license maintenance fees. The amount due under the agreement was $10,000 at September 30, 2024. The License Agreement with Teleost Biopharmaceutic, LLC was terminated as of November 8, 2024. See note 11- subsequent events for additional detail. ● Various Generic Drugs ($736,983) ● Four Generic Drugs (Encore) ($1,308,270) ● Needleless Syringe License ($26,060) ● Patents ($48,420) ● Exclusive World-wide License Agreement These licenses and patents are n	NOTE 3 – INTANGIBLE ASSETS Intangible assets consisted of the following: Intangible Assets December 31, December 31, Licenses Non-Exclusive License Agreement $ 56,325 $ - Proprietary pharmaceutical drugs 10,000 - Various generic drugs 736,983 736,983 Four generic drugs (Encore) 1,308,270 1,386,766 Needleless Syringe License 26,060 - Patents 48,420 86,160 Total intangible assets $ 2,186,058 $ 2,209,910 Intangible assets are as follows: ● Non-Exclusive License Agreement ($56,325) st ● Proprietary Pharmaceutical Drugs ($10,000) ● Various Generic Drugs ($736,983) ● Four Generic Drugs (Encore) ($1,308,270) ● Needleless Syringe License ($26,060) ● Patents ($48,420) ● Exclusive World-wide License Agreement These licenses and patents are not currently in use as the Company is pre-revenue stage. Once these licenses are in use, the licenses will be amortized over its useful life.

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Accounts Payable and Accrued Expenses [Abstract]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	NOTE 5 — ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses consist of professional fees. The accounts payable and accrued expenses as of September 30, 2024 and December 31, 2023 were $831,428 and $153,719, respectively, in the accompanying consolidated balance sheet.	NOTE 4 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses consist of professional fees. The accounts payable and accrued expenses as of December 31, 2023, and December 31, 2022 were $153,719 and $12,756, respectively, in the accompanying consolidated balance sheet.

Notes Payable to Related Partie

Notes Payable to Related Parties	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Notes Payable to Related Parties [Abstract]
NOTES PAYABLE TO RELATED PARTIES	NOTE 6 – NOTES PAYABLE TO RELATED PARTIES Notes payable to related parties consisted of the following: September 30, December 31, December 2023 $ - $ 135,000 May 2024 and December 2023 31,000 24,000 August 2024 80,000 - August 2024 20,000 - September 2024 20,000 - Total notes payable to related parties $ 151,000 $ 159,000 December 2023 ($135,000) May 2024 and December 2023 ($7,000 and $24,000) August 2024 ($80,000) $0 August 2024 ($20,000) $0 September 2024 ($20,000) $0	NOTE 5 – NOTES PAYABLE TO RELATED PARTIES Notes payable to related parties consisted of the following: December 31, December 31, November 2022 - $300,000 original amount bearing no interest due upon demand $ - $ 250,000 December 2023 - $135,000 original amount bearing no interest due upon demand. 135,000 - Total notes payable to related parties $ 135,000 $ 250,000 November 2022 ($300,000) December 2023 ($ 135,00

Notes Payable

Notes Payable	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Notes Payable [Abstract]
NOTES PAYABLE	NOTE 7 — NOTES PAYABLE On September 12, 2022, the Company issued a $1,308,270 promissory note used to acquire four market-approved anti-cancer drugs. See Note 4 – Intangible Assets On March 4, 2024, in connection with the Merger, Public ANEW entered into a convertible promissory note and Securities Purchase Agreement (“SPA”) with certain accredited investors (the “Redwoods PIPE Investors”) for an aggregate purchase price of up to $2,000,000 (the “Redwoods PIPE Financing”), which included 750,000 bonus shares of common stock. Upon the closing of the Redwoods PIPE Financing (funded and closed in connection with the closing of the Merger on June 21, 2024), which totaled $1,950,000, of which $1,768,661 was used by the Company to settle transaction costs. The Company received approximately $181,339 in net cash proceeds. On April 22, 2024, prior to the closing of the Business Combination Agreement, ANEW Medical (Wyoming) entered into a convertible promissory note and Securities Purchase Agreement (“SPA”) with certain accredited investors (the “ANEW PIPE Investors”) for an aggregate purchase price of up to $2,000,000 (the “ANEW PIPE Financing”), which included 900,000 bonus shares of common stock. Upon the closing of the ANEW PIPE Financing (funded and closed in connection with the closing of the Merger on June 21, 2024), which totaled $1,950,000 initially, of which $1,000,000 was used by the Company to settle transaction costs. The Company received approximately $1,000,000 in cash proceeds during the nine months ended September 30, 2024 and $50,000 during the three months ended September 30, 2024. Both convertible promissory notes, Redwoods PIPE Financing and ANEW PIPE Financing, bore an interest rate of 10%. During the third quarter of 2024, investors converted convertible promissory notes totaling $4,010,022, including $3,950,000 of principal and $60,022 accrued interest, through the issuance of 4,050,617 shares of common stock, of which 3,750,617 shares of common stock were issued and outstanding as of September 30, 2024. On October 2, 2024, 300,000 shares of common stock were issued to satisfy the liability in full.	NOTE 6 – NOTES PAYABLE On September 12, 2022, the Company issued a $1,308,270 promissory note to acquired four market-approved anti-cancer drugs. See Note 4 – Licenses and Patents On December 12, 2023, the Company issued a $24,000 promissory note to a member of the CEO household and not a related party. The promissory note accrued interest at a one-time interest fee of $2,460. The unpaid balance principal and interest balance was $26,460 at December 31, 2023.

Related Parties

Related Parties	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Related Parties [Abstract]
RELATED PARTIES	NOTE 8 — RELATED PARTIES On October 10, 2021, the Company signed an Employment Agreement with Dr, Joseph Sinkule to serve as the Company’s CEO for three years ending on October 9 th During November 2022, the Company advanced a shareholder $300,000 as a short-term loan. The loan is non-interest bearing and due by the end of December 2022. The shareholder repaid $50,000 during December 2022 and $250,000 in January 2023 to fully satisfy the advance. At September 30, 2024 and December 31, 2023, the loan balance was $0. On December 12, 2023, the Company issued a promissory note to a member of management. The promissory note accrued interest at a one-time interest fee of $2,460, which was paid off as of September 30, 2024. The unpaid principal balance was $31,000 and $24,000 at September 30, 2024 and December 31, 2023, respectively. On August 27, 2024, the Company issued a promissory note to a member of management. The promissory note accrues no interest. The unpaid principal balance was $80,000 and $0 at September 30, 2024 and December 31, 2023, respectively. On August 27, 2024, the Company issued a promissory note to a member of management. the promissory note accrues no interest. The unpaid principal balance was $20,000 and $0 at September 30, 2024 and December 31, 2023, respectively. At September 30, 2024 and December 31, 2023, the aggregate related party payable was $151,000 and $159,000, respectively.	NOTE 9 – RELATED PARTIES On June 8, 2020, the Company signed a Management Consulting Services Agreement with an individual to provide services to the Company. In addition, the individual has been appointed a director and an officer of the Company. The individual is compensated with $10,000 per month. At December 31, 2023, the individual is owed $55,000 under the consulting agreement with the Company. On October 10, 2021, the Company signed an Employment Agreement with Dr, Joseph Sinkule to serve as the Company’s CEO for three years ending on October 9 th During November 2022, the Company advanced a shareholder $300,000 as a short-term loan. The loan is non-interest bearing and due by the end of December 2022. The shareholder repaid $50,000 during December 2022 and $250,000 in January 2023 to fully satisfy the advance. At December 31, 2023 and 2022, the loan balance was $-0- and $250,000, respectively and is reported in due from related party in the accompanying consolidated balance sheets. On December 1, 2023, the Company issued a promissory note to two members of management in the amount of $135,000. The promissory note did not accrue interest. The unpaid principal balance was $135,000 at December 31, 2023. On December 12, 2023, the Company issued a $24,000 promissory note to a member of the CEO household and not a related party. The promissory note accrued interest at a one-time interest fee of $2,460. The unpaid balance principal and interest balance was $26,460 at December 31, 2023.

Stockholder's Equity

Stockholder's Equity	9 Months Ended
	Sep. 30, 2024
Stockholder's Equity [Abstract]
STOCKHOLDER’S EQUITY	NOTE 9 — STOCKHOLDER’S EQUITY On June 21, 2024, the Business Combination, among other transactions contemplated by the Business Combination Agreement, was completed. The transaction was accounted as a reverse recapitalization in accordance with GAAP. Under this method of accounting, Redwoods was treated as the “acquired” company for financial reporting purposes. Accordingly, for accounting purposes, the financial statements of the Combined Company represent a continuation of the financial statements of Klotho with the Transactions treated as the equivalent of Klotho issuing shares for the net assets of Redwoods, accompanied by a recapitalization. Under this method of accounting, Redwoods was treated as the acquired company for financial reporting purposes. Accordingly, for accounting purposes, the Merger was treated as the equivalent of the Company issuing shares for the net assets of Redwoods, accompanied by a recapitalization. The net assets of Redwoods were stated at historical cost with no goodwill or other intangible assets recorded. See “NOTE 1 — Organization and Business Description” for detail. Equity Incentive Plan In connection with the Business Combination, the Company’s Board adopted, and the Company’s stockholders approved, the Equity Incentive Plan (“Equity Incentive Plan”). Although the Company does not have a formal policy with respect to the grant of equity incentive awards to the Company’s executive officers, the Company believes that equity awards provide Company’s executive officers with a strong link to the Company’s long-term performance, create an ownership culture and help to align the interests of the Company’s executives and the Company’s stockholders. In addition, Company believes that equity awards with a time-based vesting feature promote executive retention because this feature provides incentives to Company’s executive officers to remain in Klotho’s employment during the applicable vesting period. Accordingly, Company’s board of directors periodically reviews the equity incentive compensation of the Company’s executive officers and from time to time may grant equity incentive awards to them. During the three months ended September 30, 2024, the Company granted 3,144,000 shares at a weighted average fair value of $0.94 per share, with various vesting schedules, resulting in share-based compensation expense of $1,952,851. During the nine months ended September 30, 2024 stock-based compensation expense totaled $1,990,366.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 10 — COMMITMENTS AND CONTINGENCIES From time to time, the Company is subject to various legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. Although the outcome of the various legal proceedings and claims cannot be predicted with certainty, management does not believe that any of these proceedings or other claims will have a material effect on the Company’s business, financial condition, results of operations or cash flows. Material Contracts On November 27, 2014, the Company signed a License Agreement and a Manufacturing and Supply Agreement for the monoclonal antibody development license and supply agreement and related manufacturing with Reliance Life Sciences (RLS), the life science arm of Reliance Industries Pvt Ltd, the largest private company in India. The contract expires on November 27, 2024 with a 10-year renewal option. The License Agreement entitles the Company to pay $100,000 per product for a total of three products with milestone payments for meeting certain criteria. In addition, the Company will pay a quarterly royalty payment of 5% on net sales of finished products. The Manufacturing and Supply Agreement contains an estimated acquisition price of active pharmaceutical ingredients (API) of $350,000 per Kg for each product developed. As of September 30, 2024, the Company has not generated any activity under the agreement. On October 19, 2022, the Company signed an M&A/Capital Markets Advisory Agreement with Chardan Capital Markets to advise and assist the Company in negotiating the terms and conditions with respect to a potential sale, purchase, merger, joint venture, business combination, material change of control, or similar transaction involving the Company and a strategic acquirer and/or private or publicly listed entity or business, including a Special Purpose Acquisition Company (SPAC), and with respect to any offerings of any equity, equity-linked or debt securities of the Company or any other party to a financing transaction and perform such other financial advisory services to the Company. At the close of the merger on June 21, 2024, the Company paid $3.0 million and 1.5 million in common shares for M&A advisory fees and deferred underwriting fees. On August 20, 2024, the Company signed a Capital Markets Advisory Agreement with Chardan Capital Markets to assist with additional fundraising. On June 13, 2024, RWOD and Klotho entered into a forward purchase agreement with (i) Meteora Capital Partners, LP (“MCP”), (ii) Meteora Select Trading Opportunities Master, LP (“MSTO”), and (iii) Meteora Strategic Capital, LLC (“MSC” and, collectively with MCP and MSTO, the “Seller”) (the “Forward Purchase Agreement”). Redwoods is the holder of the asset and Sponsor and is also a counterparty to Klotho. Upon Closing of the merger on June 21, 2024 and on September 30, 2024, the value of the contract for the Company was $0 as the contract created no receivable or obligation for the Company. On September 19, 2024, the Company modified the settlement amount price of the contract to $2.00 and the shares held with Meteora are able to be sold at Meteora’s sole discretion, with the reset price subject to weekly changes. The Company will assess the Company obligation and value the contract in the future periods based on fair value and record changes on the fair value in the Condensed Consolidated Statements of Operations. The Company entered into several employment, advisory, and consulting agreements during the quarter. On August 15 th th NASDAQ Deficiencies On August 16, 2024, the Company received two delinquency notification letters (the “Notices”) from the Nasdaq Stock Market LLC (“Nasdaq”) due to the Company’s non-compliance with Nasdaq Listing Rules 5450(b)(2)(C) and 5450(b)(2)(A). The Notices cite the Company’s (a) not being in compliance with the minimum Market Value of Publicly Held Shares (“MVPHS”) requirement as set forth in Nasdaq Listing Rule 5450(b)(2)(C) and (b) not being in compliance with the minimum Market Value of Listed Securities (MVLS) requirement as set forth in Nasdaq Listing Rule 5450(b)(2)(A). In accordance with Nasdaq Listing Rule 5810(c)(3)(D), the Company has been provided 180 calendar days, or until February 12, 2025, to regain compliance. To regain compliance, prior to February 12, 2025, (a) the Company’s minimum market value of publicly held shares must close at $15,000,000 or more for a minimum of 10 consecutive business days and (b) the Company’s minimum market value of listed securities must close at $50,000,000 or more for a minimum of 10 consecutive business days. If the Company fails to timely regain compliance with Nasdaq Listing Rules, the Company’s common stock will be subject to delisting from Nasdaq. As part of its compliance plan, the Company is evaluating a change in Nasdaq listing tiers and alternate means of qualification, including but not limited to the shareholder equity standard of qualification. On October 15, 2024, the Company received a delinquency notification letter (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) due to the failure of the Company’s common stock to maintain a minimum bid price of $1 per share for 30 consecutive business days as required by Nasdaq Listing Rule 5450(a)(1). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until April 14, 2025, to regain compliance. To regain compliance, prior to April 14, 2025, the closing bid price of the Company’s common stock must be at least $1 for a minimum of ten consecutive business days. If the Company fails to timely regain compliance with Nasdaq Listing Rules, the Company’s common stock will be subject to delisting from Nasdaq.	NOTE 11 – COMMITMENTS AND CONTINGENCIES From time to time, the Company is subject to various legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. Although the outcome of the various legal proceedings and claims cannot be predicted with certainty, management does not believe that any of these proceedings or other claims will have a material effect on the Company’s business, financial condition, results of operations or cash flows. Material Contracts On November 27, 2014, the Company signed a License Agreement and a Manufacturing and Supply Agreement for the monoclonal antibody development license and supply agreement and related manufacturing with Reliance Life Sciences (RLS), the life science arm of Reliance Industries Pvt Ltd, the largest private company in India. The contract expires on November 27, 2024 with a 10-year renewal option. The License Agreement entitles the Company to pay $100,000 per product for a total of three products with milestone payments for meeting certain criteria. In addition, the Company will pay a quarterly royalty payment of 5% on net sales of finished products. The Manufacturing and Supply Agreement contains an estimated acquisition price of active pharmaceutical ingredients (API) of $350,000 per Kg for each product developed. As of December 31, 2023, the Company has not generated any activity under the agreement. On October 19, 2022, the Company signed an M&A/Capital Markets Advisory Agreement with Chardan Capital Markets to advise and assist the Company in negotiating the terms and conditions with respect to a potential sale, purchase, merger, joint venture, business combination, material change of control, or similar transaction involving the Company and a strategic acquirer and/or private or publicly listed entity or business, including a Special Purpose Acquisition Company (SPAC), and with respect to any offerings of any equity, equity-linked or debt securities of the Company or any other party to a financing transaction and perform such other financial advisory services to the Company. As of December 31, 2023, there was no associated liability prior to consummating a deal under this Agreement.

Subsequent Events

Subsequent Events	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 11 — SUBSEQUENT EVENTS The Company has evaluated subsequent events pursuant to the requirements of ASC Topic 855, from the balance sheet date through the date the financial statements were issued, and has determined that the following subsequent event exists: ● Key Executive Employment Agreement ● Teleost Biopharmaceuticals ● Scientific Advisory Board ● Convertible Promissory Note	NOTE 12 – SUBSEQUENT EVENTS The Company has evaluated subsequent events pursuant to the requirements of ASC Topic 855, from the balance sheet date through the date the financial statements were issued, and has determined that the following subsequent event exists: ● On January 19, 2024, the Company entered into a Stock Purchase Agreement with an individual to sell 200,000 shares of the Company’s restricted common stock for $50,000 or $0.25 shares. The shares issued will be calculated on a post-reverse split basis. The Company has a planned 1-for-2500 reverse stock split of its common stock was not declared effective as of December 31, 2023 by FINRA to broker deals in the quotation system. The shares have not been issued to the individual on May 22, 2024. ● The Company’s S4 with Redwoods Acquisition Corp. was declared effective by the SEC on February 14, 2024. The required approval by the stockholders of Redwoods and the Company, approval by the Nasdaq Stock Market (“Nasdaq”) of the initial listing application of the combined company filed in connection with the Business Combination, and the fulfillment of other customary closing conditions is expected to be completed in Mayl 2024. ● On February 29, 2024, the Company granted three individuals, two executives and an organization 9,900,000 unregistered shares of the Company’s Common stock for services performed for the Company. The shares issued will be calculated on a post-reverse split basis. The Company has a planned 1-for-2500 reverse stock split of its common stock was not declared effective as of December 31, 2023 by FINRA to broker deals in the quotation system. The shares were valued at $43,560 or $0.0044 per share. The shares have not been issued to the individuals, executives or the university on May 22, 2024. ● On March 1, 2024, the Company filed a Certificate of Designation with the State of Wyoming to authorize 160,000 shares of Series D Preferred Stock with a par value of $0.001. The Series D Preferred Stock shall earn cumulative cash dividend at the annual rate of 6.0% of the original purchase price per share. Each Series D Preferred Stock shall be converted into such number of fully paid and nonassessable shares of common stock as determined by (i) dividing the original issue price by the automatic conversion rate and (ii) and dividing by the result quotient of ten (10). Each share of Series D Preferred Stock shall automatically be converted into shares of the Company stock prior to the consummation of the Company’s SPAC transaction. ● On March 4, 2024, the Company sold 50,000 shares of Series D Preferred Stock for $125,000 or $2.5 per share to an investor. In addition, the investor was granted 100,000 shares of =Series D Preferred Stock as a commitment fee and a warrant to purchase 1,500,000 shares of the Company’s unregistered common stock. The warrant has an excise price of $2.5 per share and expires on March 4, 2027. The Company will value the warrant using the Black-Scholes-Merton valuation model for estimating the fair value of call options. ● On March 15, 2024, the Company signed a Management Consulting Services Agreement with an individual in exchange of 30,000 shares of Series B Preferred stock originally issued on November 1, 2021. On March 31, 2024, the Company cancelled the 30,000 shares of Series B Preferred Stock. The individual is granted a call option for 3,000,000 unregistered shares of the Company’s Common stock at a $30 acquisition price. The call option expires on March 15, 2029. The shares issued will be calculated on a post-reverse split basis. The Company has a planned 1-for-2500 reverse stock split of its common stock was not declared effective as of December 31, 2023 by FINRA to broker deals in the quotation system. The shares were valued at $18,000 or $0.006 per share. The shares have not been issued to the individuals, executives or the university on May 22, 2024. ● On March 15, 2024, the Company signed a Management Consulting Services Agreement to an individual for services to the Company. The individual is compensated with a call option for 1,000,000 unregistered shares of the Company’s Common stock at a $10 acquisition price. The call option expires on March 15, 2029. The shares issued will be calculated on a post-reverse split basis. The Company has a planned 1-for-2500 reverse stock split of its common stock was not declared effective as of December 31, 2023 by FINRA to broker deals in the quotation system. The shares were valued at $6,000 or $0.006 per share. The shares have not been issued to the individuals, executives or the university on May 22, 2024. ● On March 15, 2024, the Company signed a Management Consulting Services Agreement with a university for services to the Company. The university is compensated with a call option for 2,000,000 unregistered shares of the Company’s Common stock at a $20 acquisition price. The call option expires on March 15, 2029. The Company has a planned 1-for-2500 reverse stock split of its common stock was not declared effective as of December 31, 2023 by FINRA to broker deals in the quotation system. The shares were valued at $12,000 or $0.006 per share. The shares have not been issued to the individuals, executives or the university on May 22, 2024. ● On March 25, 2024, the Company signed an Equity for Consulting Agreement with an individual to serve as the Company’s Chief Business Officer. The individual is compensated with 1,000,000 unregistered shares of the Company’s Common stock and $10,000 per month effective the first day of Company’s de-SPAC and public trading. The shares issued will be calculated on a post-reverse split basis. The Company has a planned 1-for-2500 reverse stock split of its common stock was not declared effective as of December 31, 2023 by FINRA to broker deals in the quotation system. The shares were valued at $6,700 or $.0067 per share. The shares have not been issued to the individual on May 22, 2024. ● On March 27, 2024, the Company amended the December 1, 2023 license agreement with TransferTech Sherbooke to remove the equity compensation of $50,000 in unregistered shares of the Company’s common stock for a lump sum cash payment of $50,000 within 10 days after the pending merger with Redwoods Acquisition Corp. The December 1, 2023 license agreement with TransferTech Sherbooke contains the rights to develop and commercialize the technology of a “Needleless Syringe”. On March 31, 2024, the Company cancelled 50,000 authorized but unissued unregistered shares of the Company’s Common stock which were due under the agreement. ● On March 28, 2024, the Company signed a Securities Purchase Agreement with an investor for a $1,300,000 convertible promissory note which will fund upon closing the business combination with Redwoods Acquisition Corp under the Company’s S-4 declared effective on February 14, 2024. The business combination is expected to close in May 2024. This convertible promissory note will mature 24 months after the aforementioned closing date. The interest on this note shall commence accruing on the original issuance date and shall be payable, at the Company’s option, either (i) in cash at 10% per annum or (ii) in freely tradable common shares (at the lower of the conversion price or 10% discount to the lowest of 5-day VWAP prior to the interest payment date) at 15% per annum. In addition, the convertible promissory note may be converted upon the aforementioned closing of the business combination at $9.00 per share; provided, however, the conversion price shall be subject to a conversion reset as set forth in this convertible note payable. The floor conversion price is the floor price that is in compliance with the requirements of the Nasdaq Stock Market LLC or another national exchange. ● On March 28, 2024, the Company signed a Securities Purchase Agreement with an investor for a $700,000 convertible promissory note which will fund upon closing the business combination with Redwoods Acquisition Corp under the Company’s S-4 declared effective on February 14, 2024. The business combination is expected to close in May 2024. This convertible promissory note will mature 24 months after the aforementioned closing date. The interest on this note shall commence accruing on the original issuance date and shall be payable, at the Company’s option, either (i) in cash at 10% per annum or (ii) in freely tradable common shares (at the lower of the conversion price or 10% discount to the lowest of 5-day VWAP prior to the interest payment date) at 15% per annum. In addition, the convertible promissory note may be converted upon the aforementioned closing of the business combination at $9.00 per share; provided, however, the conversion price shall be subject to a conversion reset as set forth in this convertible note payable. The floor conversion price is the floor price that is in compliance with the requirements of the Nasdaq Stock Market LLC or another national exchange. ● On April 22, 2024, the Company signed a $2,000,000 convertible promissory note with an investor. The convertible promissory note will mature on April 22, 2026. The note is expected to fund upon closing the business combination with Redwoods Acquisition Corp under the Company’s S-4 declared effective on February 14, 2024. The business combination is expected to close in May 2024.The interest on this note shall be payable, at the Company’s option, either (i) in cash at 10% per annum or (ii) in freely tradable Common Shares (at the lower of the conversion price or 10% discount to the lowest of 5-day VWAP prior to the interest payment date) at 15% per annum. In addition, the convertible promissory note may be converted upon the aforementioned closing of the business combination at $9.00 per share; provided, however, the conversion price shall be subject to a conversion reset as set forth in this convertible note payable. The floor conversion price is the floor price that is in compliance with the requirements of the Nasdaq Stock Market LLC or another national exchange.

Equity Transactions

Equity Transactions	12 Months Ended
	Dec. 31, 2023
Equity Transactions [Abstract]
EQUITY TRANSACTIONS	NOTE 7 – EQUITY TRANSACTIONS The Company was established with three classes of stock, common stock – 1,500,000,000 shares authorized at a par value of $0.0001 Class B preferred stock 500,000 shares authorized at a par value of $0.001 and Class C preferred stock 5,000,000 shares authorized at a par value of $0.0001. On December 31, 2023 and 2022, the Company issue and outstanding common stock was 1,044,861,360 shares, 405,250 shares of Class B preferred stock and 1,000,000 shares of Class C preferred stock. On November 1, 2021, the shareholders of the Company approved a 1-for-2500 reverse split. As of December 31, 2023, the reverse split has not been declared effective by FINRA to broker deals in the quotation system. On February 1, 2022, the Company entered into a Stock Purchase Agreement with an individual to sell 1,666,667 shares of the Company’s common stock for $250,000 or $0.15 shares. The shares issued will be calculated on a post-reverse split basis. The Company has a planned 1-for-2500 reverse stock split of its common stock was not declared effective as of December 31, 2023 by FINRA to broker deals in the quotation system. The shares have not been issued to the individual at December 31, 2023. On February 22, 2022, the Company entered into a consulting agreement to provide service to the Company. Pursuant to the agreement, the consultant is compensated with 1,000,000 shares of the Company’s restricted common stock. The shares were valued at $0.0014 per share. The shares have not been issued to the consultant on December 31, 2023. On September 12, 2022, the Company entered into a Stock Purchase Agreement with an individual to sell 2,000,000 shares of the Company’s common stock for $500,000 or $0.25 shares. The shares issued will be calculated on a post-reverse split basis. The Company has a planned 1-for-2500 reverse stock split of its common stock was not declared effective as of December 31, 2023 by FINRA to broker deals in the quotation system. The shares have not been issued to the individual at December 31, 2023. On August 15, 2023, the Company entered into a Stock Purchase Agreement with an individual to sell 300,000 shares of the Company’s restricted common stock for $75,000 or $0.25 shares. The shares issued will be calculated on a post-reverse split basis. The Company has a planned 1-for-2500 reverse stock split of its common stock was not declared effective as of December 31, 2023 by FINRA to broker deals in the quotation system. The shares have not been issued to the individual on December 31, 2023. On August 15, 2023, the Company entered into a Stock Purchase Agreement with an individual to sell 100,000 shares of the Company’s restricted common stock for $25,000 or $0.25 shares. The shares issued will be calculated on a post-reverse split basis. The Company has a planned 1-for-2500 reverse stock split of its common stock was not declared effective as of December 31, 2023 by FINRA to broker deals in the quotation system. The shares have not been issued to the individual on December 31, 2023.

Material Contracts

Material Contracts	12 Months Ended
	Dec. 31, 2023
Material Contracts [Abstract]
MATERIAL CONTRACTS	NOTE 8 – MATERIAL CONTRACTS On November 27, 2014, the Company signed a License Agreement and a Manufacturing and Supply Agreement for the monoclonal antibody development license and supply agreement and related manufacturing with Reliance Life Sciences (RLS), the life science arm of Reliance Industries Pvt Ltd, the largest private company in India. The contract expires on November 27, 2024 with a 10-year renewal option. The License Agreement entitles the Company to pay $100,000 per product for a total of three products with milestone payments for meeting certain criteria. In addition, the Company will pay a quarterly royalty payment of 5% on net sales of finished products. The Manufacturing and Supply Agreement contains an estimated acquisition price of active pharmaceutical ingredients (API ) of $350,000 per Kg for each product developed. As of December 31, 2023, the Company has not generated any activity under the agreement. On October 1, 2020, the Company entered into a three-year Management Consulting Services Agreement with an individual to provide various services including raising funds for the Company. The contact terminates on December 31, 2023. The consultant is compensated with 3% of the net proceeds of the any contractual relationship and equity compensation of up to 3% of the value of the business development contract with restricted share of the Company’s common stock. As of December 31, 2023, the Company has not generated any activity under the agreement. On November 19, 2021, the Company sign a consulting agreement with an individual to raise capital for new medical products and commercialize such products for a 5% commission fee. As of December 31, 2023, the Company has not generated any activity under the agreement. On January 24, 2022, the Company signed an exclusive, world-wide License Agreement with the University of Barcelona for a cell and/or gene therapy that has shown compelling activity in animal models of human Alzheimer’s disease and amyotrophic lateral sclerosis (“ALS” or “Lou Gehrig’s disease”). The gene therapy will also be applied to age-related diseases and rare (“Orphan”) diseases. Beginning on December 15, 2022, the Quarterly license fee is 10,000 Euros. In addition, the Company will pay a Royalty equal to 3% of net sales of finished products. For the years ended December 31, 2023 and 2022, the Company owes $-0- under the agreement. On April 5, 2022, the Company entered into a Business Development and Consulting Agreement with an individual to serve as the Company’s chief business officer. Beginning on May 1, 2022, the consultant is compensated with $10,000 a month for the three months ended July 31, 2022 and $15,000 thereafter. The consultant works approximately 80 hours a month. In addition to cash considerations, the consultant was compensated with 1,000,000 shares of the Company’s common stock valued at $1,400 or $0.0014 per share. As of December 31, 2023, the shares have not been issued to the consultant. The Contract was terminated on August 15, 2022 with no amount due to the consultant. On October 19, 2022, the Company sign a M&A/Capital Markets Advisory Agreement with a firm to advise and assist the Company in negotiating the terms and conditions with respect to a potential sale, purchase, merger, joint venture, business combination, material change of control, or similar transaction involving the Company and a strategic acquirer and/or private or publicly listed entity or business, including a Special Purpose Acquisition Company (SPAC), and with respect to any offerings of any equity, equity-linked or debt securities of the Company or any other party to a financing transaction and perform such other financial advisory services to the Company. The Company will compensate the firm with an M&A fee, a financing fee and expenses. Upon consummation of a transaction, the Company will pay the firm an M&A fee consisting of an aggregate of a sum equal to the greater of $2,500,000 or the sum of the following amounts: ● four percent (4.0%) of the first $100 MM of Aggregate Value; ● three percent (3.0%) of any amount of the Aggregate Value between $100 MM and $200 MM; ● two percent (2.0%) of any amount of the Aggregate Value between $200 MM and $300MM; ● one percent (1.0%) of any amount of the Aggregate Value exceeding $300 MM In addition, the Company will pay the firm a financing fee of seven percent (7%) of the aggregate amount of proceeds received from investors in the financing of any equity or equity-linked securities and three percent (3%) of the aggregate amount of proceeds received from the Financing of any non-equity-linked debt securities and credit facilities. As of December 31, 2023, the Company owes $-0- under the agreement. On February 1, 2023, the Company entered into a Consulting Agreement with an individual to advise the Company in the general field of melanocortins, melanocortin receptors and melanocortin receptor-binding molecules. The consultant will be compensated with $2,500 for 12 months ending on February January 31, 2024. The Consultant was paid $10,000 upfront for the first four months and $2,500 during March 2023 for an aggregate of $12,500. The Contract was terminated during March 2023 and with no amount due to or due from the Consultant.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2023
Income Taxes [Abstract]
INCOME TAXES	NOTE 10 – INCOME TAXES The Company’s policy is to provide for deferred income taxes based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates that will be in effect when the differences are expected to reverse. We did not provide any current or deferred U.S. federal income tax provision or benefit for any of the periods presented because we have experienced operating losses since inception. When it is more likely than not that a tax asset cannot be realized through future income the Company must allow for this future tax benefit. We provided a full valuation allowance on the net deferred tax asset, consisting of net operating loss carryforwards, because management has determined that it is more likely than not that we will not earn income sufficient to realize the deferred tax assets during the carryforward period. The Company is not aware of any uncertain tax position that, if challenged, would have a material effect on the financial statements for the year ended December 31, 2023 or during the prior three years applicable under FASB ASC 740. We did not recognize any adjustment to the liability for uncertain tax position and therefore did not record any adjustment to the beginning balance of accumulated deficit on the balance sheet. All tax returns for the Company remain open for examination. The provision for income taxes differs from the amount computed by applying the statutory federal income tax rate to income before provision for income taxes. The sources and tax effects of the differences for the periods presented are as follows: 2023 2022 Income tax provision at the federal statutory rate 28 % 21 % Effect on operating losses (28 )% (21 )% The net deferred tax assets consist of the following: December 31, December 31, Deferred tax asset $ 1,098,630 $ 675,406 Valuation allowance (1,0968,630 ) (675,406 ) Net deferred tax asset $ - $ - The change in the valuation allowance for the year ended December 31, 2022 was an increase of $423,224.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Summary of Significant Accounting Policies [Abstract]
Going Concern	Going Concern The accompanying unaudited consolidated financial statements have been prepared as if the Company will continue as a going concern. The Company has incurred significant operating losses and negative cash flows from operations since inception. As of September 30, 2024, the Company had cash of approximately $51,000 and an accumulated deficit of approximately $8.5 million. The Company has incurred recurring losses, has experienced recurring negative operating cash flows, and requires significant cash resources to execute its business plans. The Company is dependent on obtaining additional working capital funding from the sale of equity and/or debt securities in order to continue to execute its development plans and continue operations. Without additional funding, there is substantial doubt about the Company’s ability to continue as a going concern for twelve months from the date of these financial statements.	Going Concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred material recurring losses from operations. The Company has not generated material revenues since inception and has generated losses totaling $3,923,677 since inception. The consolidated financial statements do not contain any adjustments to reflect the possible future effects on the classification of assets or the amounts and classification of liability that may result should the Company be unable to continue as a going concern.
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The Company prepares its consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC. The Company prepared the Financial Statements, without audit, pursuant to the rules and regulations of the SEC applicable to quarterly reporting on Form 10-Q and reflect, in management’s opinion, all adjustments necessary to present fairly the financial information. All such adjustments are of a normal recurring nature. Certain information and footnote disclosures normally included in financial statements, prepared in accordance with generally accepted accounting principles, have been consolidated or omitted as permitted by such rules and regulations. These Financial Statements should be read in conjunction with the consolidated financial statements and related notes included in the 2023 Annual Report. Results of operations for interim periods are not necessarily indicative of annual results.	Basis of Presentation and Principles of Consolidation The Company prepares its consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC. The Company prepared the Financial Statements pursuant to the rules and regulations of the SEC and reflect, in management’s opinion, all adjustments necessary to present fairly the financial information. All such adjustments are of a normal recurring nature. Certain information and footnote disclosures normally included in financial statements, prepared in accordance with generally accepted accounting principles, have been consolidated or omitted as permitted by such rules and regulations.
Reclassification	Reclassification Certain prior year amounts have been reclassified for comparative purposes to conform to the current-year financial statement presentation. These reclassifications had no effect on previously reported results of operations and were not material.	Reclassification Certain prior year amounts have been reclassified for comparative purposes to conform to the current-year financial statement presentation. These reclassifications had no effect on previously reported results of operations and were not material.
Emerging Growth Company	Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates	Use of Estimates The preparation of unaudited consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires the Company to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and the accompanying notes. Such estimates include life of intangible assets, accrued liabilities, income taxes, long-lived assets, and deferred tax valuation allowances. These estimates generally involve complex issues and require management to make judgments, involve analysis of historical and future trends that can require extended periods of time to resolve, and are subject to change from period to period. In all cases, actual results could differ materially from estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents represent cash on hand, demand deposits, and other short-term highly liquid investments placed with banks, which have original maturities of three months or less and are readily convertible to known amounts of cash.	Cash and Cash Equivalents Cash and cash equivalents represent cash on hand, demand deposits, and other short-term highly liquid investments placed with banks, which have original maturities of three months or less and are readily convertible to known amounts of cash.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. As of September 30, 2024, the Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company did not hold cash in excess of FDIC insurance coverage at a financial institution as of December 31, 2023 and 2022.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The assets and liabilities are valued using a fair market basis as defined in the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) ASC 820, Fair Value Measurement. Fair value is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date. The Company uses a three-level hierarchy established by the FASB that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach and cost approach). The levels of the fair value hierarchy are described below: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs with little or no market data available, which require the reporting entity to develop its own assumptions. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. Financial assets and liabilities are classified in their entirety based on the most conservative level of input that is significant to the fair value measurement. Fair value measurements at reporting date using: Fair value Quoted prices in active markets for identical liabilities (Level 1) Significant other Significant unobservable inputs Liabilities: Representative warrant liabilities, September 30, 2024 $ 21,200 $ - $ - $ 21,200 Liabilities: Representative warrant liabilities, December 31, 2023 $ - $ - $ - $ - The following tables present a reconciliation of the Level 3 Private Warrants liabilities: Nine Months Ended 2024 2023 Representative warrant liabilities, January 1 $ - $ - Issuances/Assumptions 22,525 - Change in fair value (1,325 ) - Representative warrant liabilities, September 30 $ 21,200 $ - Three Months Ended 2024 2023 Representative warrant liabilities, July 1 $ 62,222 $ - Change in fair value (41,022 ) - Representative warrant liabilities, September 30 $ 21,200 $ -	Fair Value of Financial Instruments The assets and liabilities are valued using a fair market basis as defined in the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) ASC 820, Fair Value Measurement. Fair value is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date. The Company uses a three-level hierarchy established by the FASB that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach and cost approach). The levels of the fair value hierarchy are described below: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs with little or no market data available, which require the reporting entity to develop its own assumptions. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. Financial assets and liabilities are classified in their entirety based on the most conservative level of input that is significant to the fair value measurement. The Company did not identify any assets or liabilities that are required to be adjusted on the balance sheet to fair value as of December 31, 2023 and 2022.
Intangible Assets	Intangible Assets The Company’s intangible assets consist of acquired medical licenses and patents. The Company acquires medical licenses for the treatment of medical conditions to market and sell in the future. The initial asset cost is the cost to acquire the license. Once in use, the Company amortizes the license cost over the useful life using the straight-line method. As part of the licensing agreements, the Company acquires patents and records the cost to acquire patents as the initial asset cost. Once the patents are approved and in use, assuming no litigations expenses, the Company amortizes the patent cost over the useful life using the straight-line method. The amortization period will not exceed the lifespan of the protection afforded by the patent. If the expected useful life of the patent is even shorter, the Company will use the useful life for amortization purposes. Thus, the shorter of a patent’s useful life or legal life will be used for the amortization period.	Intangible Assets The Company’s intangible assets consist of acquired medical licenses and patents. The Company acquires medical licenses for the treatment of medical conditions to market and sell in the future. The initial asset cost is the cost to acquire the license. Once in use, the Company amortizes the license cost over the useful life using the straight-line method. As part of the licensing agreements, the Company acquires patents and records the cost to acquire patents as the initial asset cost. Once the patents are approved and in use, assuming no litigations expenses, the Company amortizes the patent cost over the useful life using the straight-line method. The amortization period will not exceed the lifespan of the protection afforded by the patent. If the expected useful life of the patent is even shorter, the Company will use the useful life for amortization purposes. Thus, the shorter of a patent’s useful life or legal life will be used for the amortization period.
Impairment of Long-Lived and Intangible Assets	Impairment of Long-Lived and Intangible Assets The Company assesses the impairment of long-lived and intangible assets periodically, or at least annually, and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors considered important, which could trigger an impairment review, include the following: significant underperformance relative to historical or projected future cash flows; significant changes in the manner of use of the assets or the strategy of the overall business; and significant negative industry trends. When management determines that the carrying value of long-lived and intangible assets may not be recoverable, impairment is measured as the excess of the assets’ carrying value over the estimated fair value. Management is not aware of any other impairment charges that may currently be required; however, the Company cannot predict the occurrence of events that might adversely affect the reported values in the future. On an annual basis, the Company tests the long-lived and intangible assets for impairment based on the projected net present value of cash flows for each asset. Prior to the annual impairment test, if circumstances change and a long-lived or intangible asset is deemed impaired, an impairment loss will be immediately recognized in the statements of operations. At December 31, 2023, the date of the last impairment test, it was determined that the estimated fair value of the intangible assets exceeded the carrying value of the assets by 50%, indicating no impairment.	Impairment of Long-Lived and Intangible Assets The Company assesses the impairment of long-lived and intangible assets periodically, or at least annually, and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors considered important, which could trigger an impairment review, include the following: significant underperformance relative to historical or projected future cash flows; significant changes in the manner of use of the assets or the strategy of the overall business; and significant negative industry trends. When management determines that the carrying value of long-lived and intangible assets may not be recoverable, impairment is measured as the excess of the assets’ carrying value over the estimated fair value. Management is not aware of any other impairment charges that may currently be required; however, the Company cannot predict the occurrence of events that might adversely affect the reported values in the future. On an annual basis, the Company tests the long-lived and intangible assets for impairment based on the projected net present value of cash flows for each asset. Prior to the annual impairment test, if circumstances change and a long-lived or intangible asset is deemed impaired, an impairment loss will be immediately recognized in the statements of operations. At December 31, 2023, the date of the last impairment test, it was determined that the estimated fair value of the intangible assets exceeded the carrying value of the assets by 50%, indicating no impairment.
Revenue Recognition	Revenue Recognition The Company is in a pre-revenue state and does not generate revenue. When the Company commences to derive revenue, those contracts will be accounted in accordance with ASU 2014-09, Revenue from Contracts with Customers (Topic ASC 606).	Revenue Recognition The Company is in a pre-revenue state and does not generate revenue. When the Company commences to derive revenue, those contracts will be accounted in accordance with ASU 2014-09, Revenue from Contracts with Customers (Topic ASC 606).
Income Taxes	Income Taxes The Company uses the asset and liability method of accounting for income taxes in accordance with ASU 740, “Income Taxes”. Under this method, income tax expense is recognized as the amount of: (i) taxes payable or refundable for the current year and (ii) future tax consequences attributable to differences between the consolidated financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of available evidence it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company is subject to Income tax filings requirements in U.S. federal and various state jurisdictions. The Company’s tax returns for years from 2021, 2022, and 2023 are subject to U.S. federal, state, and local income tax examinations by tax authorities. The Company reports income tax related interest and penalties within the income tax line item on the consolidated statements of operations. The Company likewise reports the reversal of income tax-related interest and penalties within such line item to the extent the Company resolves the liabilities for uncertain tax positions in a manner favorable to the accruals.	Income Taxes The Company uses the asset and liability method of accounting for income taxes in accordance with ASU 740, “Income Taxes”. Under this method, income tax expense is recognized as the amount of: (i) taxes payable or refundable for the current year and (ii) future tax consequences attributable to differences between the consolidated financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of available evidence it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company is subject to Income tax filings requirements in U.S. federal and various state jurisdictions. The Company’s tax returns for years from 2021, 2022, and 2023 are subject to U.S. federal, state, and local income tax examinations by tax authorities. The Company reports income tax related interest and penalties within the income tax line item on the consolidated statements of operations. The Company likewise reports the reversal of income tax-related interest and penalties within such line item to the extent the Company resolves the liabilities for uncertain tax positions in a manner favorable to the accruals.
Net Loss Per Share (Basic and Diluted)	Net Loss Per Share (Basic and Diluted) Basic net loss per share is computed by dividing net loss by the weighted average number of shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares outstanding, plus the number of additional shares that would have been outstanding if the common share equivalents had been issued, if dilutive. The following table details the net loss per share calculation, reconciles between basic and diluted weighted average shares outstanding, and presents the potentially dilutive shares that are excluded from the calculation of the weighted average diluted common shares outstanding, because their inclusion would have been anti-dilutive: For the Nine Months Ended 2024 2023 Numerator: Net loss $ (4,083,109 ) $ (580,983 ) Weighted average shares outstanding (denominator for basic earnings per share) 16,588,940 15,130,393 Weighted average shares and assumed potential common shares (denominator for diluted earnings per share, treasury method) 16,588,940 15,130,393 Basic loss per share $ (0.25 ) $ (0.04 ) Diluted loss per share $ (0.25 ) $ (0.04 ) The following common share equivalents are excluded from the calculation of weighted average common shares outstanding, because their inclusion would have been anti-dilutive: For the Nine Months Ended 2024 2023 Warrants 12,030,000 12,030,000 Total potentially dilutive shares 12,030,000 12,030,000	Net Loss Per Share (Basic and Diluted) Basic net loss per common share is computed using the weighted average number of common shares outstanding. Diluted earnings per share (EPS) include additional dilution from common stock equivalents, such as stock issuable pursuant to convertible notes. Common stock equivalents are not included in the computation of diluted earnings per share when the Company reports a loss because to do so would be anti-dilutive for the periods presented. On December 31, 2023 the Company’s common stock equivalents consisted of 405,250 shares of Series B preferred stock outstanding which may be converted into 40,525,000 shares of the Company’s common stock and 851,400 shares common stock to be issued for an aggregate of 41,376,400 shares of common stock.
Research and Development Cost	Research and Development Cost Research and development (R&D) costs are expensed as incurred. R&D costs are related to the Company’s internally funded development of the Company medical licenses and patents. The Company R&D costs were $0 for the three and nine months ended September 30, 2024 and 2023, respectively.	Research and Development Cost Research and development (R&D) costs are expensed as incurred. R&D costs are related to the Company’s internally funded development of the Company medical licenses and patents. The Company had R&D costs were $-0- for the years ended December 31, 2023 and 2022, respectively.
Share-based Compensation	Share-based Compensation The Company accounts for share-based compensation in accordance with the fair value recognition provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) No. 718 and No. 505. The Company issues restricted stock to employees and consultants for their services. Cost for these transactions are measured at the fair value of the equity instruments issued at the date of grant. These shares are considered fully vested and the fair market value is recognized as an expense in the period granted. The Company recognized consulting expenses and a corresponding increase to additional paid-in-capital related to stock issued for services. For agreements requiring future services, the consulting expense is to be recognized ratably over the requisite service period. The Company recorded share-based compensation of $1,990,366 and $100,000 for the nine months ended September 30, 2024, and 2023, respectively.	Share-based Compensation The Company accounts for share-based compensation in accordance with the fair value recognition provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) No. 718 and No. 505. The Company issues restricted stock to employees and consultants for their services. Cost for these transactions are measured at the fair value of the equity instruments issued at the date of grant. These shares are considered fully vested and the fair market value is recognized as an expense in the period granted. The Company recognized consulting expenses and a corresponding increase to additional paid-in-capital related to stock issued for services. For agreements requiring future services, the consulting expense is to be recognized ratably over the requisite service period. The Company recorded share-based compensation of $-0-
Warrants	Warrants As of September 30, 2024, the fair value of the Representative Warrant liabilities was $21,200 based on the closing price of the warrants on The Nasdaq Capital Market. The fair value of the Representative Warrants was approximately $0.04 per Representative Warrant, which was based on the relative fair value to the Public Warrants. During the quarter, our Public and Private Warrants met the conditions necessary to adjust the exercise price and the redemption trigger price. As of September 30, 2024, the exercise price was $3.49 per warrant, and the redemption trigger price was $5.01. During the three months ended September 30, 2024, the fair value of the Representative warrants decreased by $41,022. During the three months ended September 30, 2024, a warrant holder exercised 130,000 warrants issued as part of the Series D Preferred Shares related to the Business Combination, with a total value of $96,200, valued as of September 27, 2024.
Related Parties	Related Parties The Company follows subtopic 850-10 of the FASB Accounting Standards Codification for the identification of related parties and disclosure of related party transactions. Pursuant to Section 850-10-20 the related parties include (a) affiliates of the Company; (b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; (c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; (d) principal owners of the Company; (e) management of the Company; (f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and (g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests. The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: (a) the nature of the relationship(s) involved; (b) description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; (c) the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and (d) amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.	Related Parties The Company follows subtopic 850-10 of the FASB Accounting Standards Codification for the identification of related parties and disclosure of related party transactions. Pursuant to Section 850-10-20 the related parties include (a) affiliates of the Company; (b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; (c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; (d) principal owners of the Company; (e) management of the Company; (f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and (g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests. The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: (a) the nature of the relationship(s) involved; (b) description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; (c) the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and (d) amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s consolidated financial statements.	Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s consolidated financial statements.
Prepaid Expenses		Prepaid Expenses The Company considers all items incurred for future services to be prepaid expenses. The prepaid expenses were $3,840 and $3,667 at December 31, 2023 and 2022, consisting of the OTC Market annual fee.
Property and equipment		Property and equipment Property and equipment are recorded at cost and depreciated on the straight-line method over the estimated useful lives. Expenditures for normal repairs and maintenance are charged to expense as incurred. The cost and related accumulated depreciation of assets sold or otherwise disposed of are removed from the accounts, and any gain or loss is included in operations.
Licenses		Licenses The Company acquires medical licenses for the treatment of medical conditions to market and sell in the future. The initial asset cost is the cost to acquire the license. Once in use, the Company amortizes the license cost over the useful life using the straight-line method.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2024
Summary of Significant Accounting Policies [Abstract]
Schedule of Financial Assets and Liabilities Based on Fair Value Measurement	Financial assets and liabilities are classified in their entirety based on the most conservative level of input that is significant to the fair value measurement. Fair value measurements at reporting date using: Fair value Quoted prices in active markets for identical liabilities (Level 1) Significant other Significant unobservable inputs Liabilities: Representative warrant liabilities, September 30, 2024 $ 21,200 $ - $ - $ 21,200 Liabilities: Representative warrant liabilities, December 31, 2023 $ - $ - $ - $ -
Schedule of Reconciliation of the Level 3 Representative Warrants liabilities	The following tables present a reconciliation of the Level 3 Private Warrants liabilities: Nine Months Ended 2024 2023 Representative warrant liabilities, January 1 $ - $ - Issuances/Assumptions 22,525 - Change in fair value (1,325 ) - Representative warrant liabilities, September 30 $ 21,200 $ - Three Months Ended 2024 2023 Representative warrant liabilities, July 1 $ 62,222 $ - Change in fair value (41,022 ) - Representative warrant liabilities, September 30 $ 21,200 $ -
Schedule of Net Loss Per Share Calculation	The following table details the net loss per share calculation, reconciles between basic and diluted weighted average shares outstanding, and presents the potentially dilutive shares that are excluded from the calculation of the weighted average diluted common shares outstanding, because their inclusion would have been anti-dilutive: For the Nine Months Ended 2024 2023 Numerator: Net loss $ (4,083,109 ) $ (580,983 ) Weighted average shares outstanding (denominator for basic earnings per share) 16,588,940 15,130,393 Weighted average shares and assumed potential common shares (denominator for diluted earnings per share, treasury method) 16,588,940 15,130,393 Basic loss per share $ (0.25 ) $ (0.04 ) Diluted loss per share $ (0.25 ) $ (0.04 )
Schedule of Common Share Equivalents are Excluded from the Calculation of Weighted Average Common Shares Outstanding	The following common share equivalents are excluded from the calculation of weighted average common shares outstanding, because their inclusion would have been anti-dilutive: For the Nine Months Ended 2024 2023 Warrants 12,030,000 12,030,000 Total potentially dilutive shares 12,030,000 12,030,000

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Intangible Assets [Abstract]
Schedule of Intangible Assets	Intangible assets consisted of the following: Intangible Assets September 30, December 31, Licenses Non-Exclusive License Agreement $ 179,821 $ 56,325 Proprietary pharmaceutical drugs 10,000 10,000 Various generic drugs 736,983 736,983 Four generic drugs (Encore) 1,308,270 1,308,270 Needleless Syringe License 26,060 26,060 Patents 48,420 48,420 Total intangible assets $ 2,309,554 $ 2,186,058	Intangible assets consisted of the following: Intangible Assets December 31, December 31, Licenses Non-Exclusive License Agreement $ 56,325 $ - Proprietary pharmaceutical drugs 10,000 - Various generic drugs 736,983 736,983 Four generic drugs (Encore) 1,308,270 1,386,766 Needleless Syringe License 26,060 - Patents 48,420 86,160 Total intangible assets $ 2,186,058 $ 2,209,910

Notes Payable to Related Part_2

Notes Payable to Related Parties (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Notes Payable to Related Parties [Abstract]
Schedule of Notes Payable to Related Parties	Notes payable to related parties consisted of the following: September 30, December 31, December 2023 $ - $ 135,000 May 2024 and December 2023 31,000 24,000 August 2024 80,000 - August 2024 20,000 - September 2024 20,000 - Total notes payable to related parties $ 151,000 $ 159,000	Notes payable to related parties consisted of the following: December 31, December 31, November 2022 - $300,000 original amount bearing no interest due upon demand $ - $ 250,000 December 2023 - $135,000 original amount bearing no interest due upon demand. 135,000 - Total notes payable to related parties $ 135,000 $ 250,000

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Income Taxes [Abstract]
Schedule of Statutory Federal Income Tax Rate to Income Before Provision for Income Taxes	The provision for income taxes differs from the amount computed by applying the statutory federal income tax rate to income before provision for income taxes. The sources and tax effects of the differences for the periods presented are as follows: 2023 2022 Income tax provision at the federal statutory rate 28 % 21 % Effect on operating losses (28 )% (21 )%
Schedule of Net Deferred Tax Assets	The net deferred tax assets consist of the following: December 31, December 31, Deferred tax asset $ 1,098,630 $ 675,406 Valuation allowance (1,0968,630 ) (675,406 ) Net deferred tax asset $ - $ -

Organization and Business Des_2

Organization and Business Description (Details) - USD ($)			9 Months Ended		12 Months Ended
	Apr. 22, 2024	Mar. 04, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Jun. 21, 2024	Aug. 15, 2023	Sep. 12, 2022	Feb. 01, 2022
Organization and Business Description [Line Items]
Valuation of the company						$ 751,400
Common stock outstanding (in Shares)			19,863,515		15,130,393	1,044,861,360
Escrow shares (in Shares)			2,875,000
Cash		$ 181,339
Number of common stock shares (in Shares)			6,000,000
Common stock valued			$ 1,986		$ 1,513	$ 104,486			$ 500,000	$ 250,000
ANEW equity value			$ 60,000,000
Per share valuation (in Dollars per share)								$ 0.25
Common stock, par value per share (in Dollars per share)			$ 0.0001		$ 0.0001	$ 0.0001
Converted newly issued share (in Shares)			1		405,250
Aggregate units (in Shares)	900,000	750,000
Settle transaction costs	$ 1,950,000	$ 1,950,000
Additional shares of redwoods’ common stock (in Shares)			19,863,515		15,130,393	1,044,861,360
Contingent consideration shares			(i)2,000,000 Contingent Consideration Shares upon the Company’s common stock achieving a closing price equal to or exceeding $12.50 for 10 trading days within a 20-day trading period in the first three years following the Closing;   (ii) 2,000,000 Contingent Consideration Shares upon the Company’s common stock achieving a closing price equal to or exceeding $15.00 for 10 trading days within a 20-day trading period in the first three years following the Closing; and   (iii) 1,000,000 Contingent Consideration Shares upon the Company’s common stock achieving a closing price equal to or exceeding $20.00 for 10 trading days within a 20-day trading period in the first five years following the Closing.
Income tax payable			$ (568,111)
Public Warrants [Member]
Organization and Business Description [Line Items]
Warrants exercisable (in Shares)			11,500,000
Private Warrants [Member]
Organization and Business Description [Line Items]
Warrants exercisable (in Shares)			530,000
Cash [Member]
Organization and Business Description [Line Items]
Cash			$ 589,081
Income Tax Payable [Member]
Organization and Business Description [Line Items]
Income tax payable			$ 568,111
Business Combination [Member]
Organization and Business Description [Line Items]
Cash							$ 181,339
Redwoods Acquisition Corp [Member]
Organization and Business Description [Line Items]
Issued shares (in Shares)			6,000,000
Assuming price per share (in Dollars per share)			$ 10
Cash			$ 8,500
ANew Medical, Inc [Member]
Organization and Business Description [Line Items]
Common stock valued			$ 60,000,000
Per share valuation (in Dollars per share)			$ 10
Common stock, par value per share (in Dollars per share)			$ 0.0001				$ 0.0001
Redwoods PIPE Investors [Member]
Organization and Business Description [Line Items]
Cash			$ 181,339
Aggregate units (in Shares)			750,000
Settle transaction costs			$ 2,000,000
ANEW PIPE Investors [Member]
Organization and Business Description [Line Items]
Issued shares (in Shares)			1
Cash			$ 589,081
Aggregate units (in Shares)			854,257
Aggregate purchase price			$ 2,000,000
Settle transaction costs			1,000,000
ANEW PIPE Financing Funds [Member]
Organization and Business Description [Line Items]
Cash			950,000
Redwoods PIPE Financing Funds [Member] | Redwoods PIPE Investors [Member]
Organization and Business Description [Line Items]
Cash			50,000
ANEW PIPE Financing Funds [Member] | ANEW PIPE Investors [Member]
Organization and Business Description [Line Items]
Cash			50,000
Common Stock [Member] | Redwoods Acquisition Corp [Member]
Organization and Business Description [Line Items]
Valuation of the company			$ 60,000,000
Common stock outstanding (in Shares)			15,130,393
Merger Sub Common Stock [Member]
Organization and Business Description [Line Items]
Common stock, par value per share (in Dollars per share)			$ 0.0001
Redwoods Common Stock [Member]
Organization and Business Description [Line Items]
Additional shares of redwoods’ common stock (in Shares)			5,000,000
Warrant [Member]
Organization and Business Description [Line Items]
Warrants exercisable (in Shares)			12,030,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)		3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 27, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Summary of Significant Accounting Policies [Line Items]
Cash		$ 51,000		$ 51,000
Generated losses total		(8,495,536)		(8,495,536)		$ (3,923,677)	$ (3,216,219)
Federal depository insurance coverage		250,000		$ 250,000		$ 250,000
Percentage of carrying value of intangible assets				50%		50%
R&D costs		0	$ 0	$ 0	$ 0	$ 0	0
Share-based compensation				1,990,366	100,000		1,400
Warrant liabilities		21,200		$ 21,200
Warrants exercise price per share (in Dollars per share)				$ 0.04
Redemption trigger price (in Dollars per share)				$ 5.01
Fair value of warrants		(41,022)		$ (1,325)
Converted shares (in Shares)				1		405,250
Prepaid expenses		$ 103,750		$ 103,750		$ 3,840	$ 3,667
Business Combination [Member]
Summary of Significant Accounting Policies [Line Items]
Business combination value	$ 96,200
Warrant [Member]
Summary of Significant Accounting Policies [Line Items]
Warrants exercise price per share (in Dollars per share)				$ 3.49
Series D Preferred Shares [Member]
Summary of Significant Accounting Policies [Line Items]
Warrants exercised (in Shares)		130,000		130,000
Series B Preferred Stock [Member]
Summary of Significant Accounting Policies [Line Items]
Converted shares (in Shares)						40,525,000
Common Stock [Member]
Summary of Significant Accounting Policies [Line Items]
Common stock, shares issued (in Shares)						851,400
Aggregate shares of common stock (in Shares)						41,376,400

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Schedule of Financial Assets and Liabilities Based on Fair Value Measurement (Details) - USD ($)	Sep. 30, 2024	Jun. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Dec. 31, 2022
Liabilities:
Representative warrant liabilities	$ 21,200
Quoted prices in active markets for identical liabilities (Level 1) [Member]
Liabilities:
Representative warrant liabilities
Significant other observable inputs (Level 2) [Member]
Liabilities:
Representative warrant liabilities
Significant unobservable inputs (Level 3) [Member]
Liabilities:
Representative warrant liabilities	$ 21,200	$ 62,222

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Reconciliation of the Level 3 Representative Warrants liabilities (Details) - Level 3 [Member] - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Schedule of Reconciliation of the Level 3 Representative Warrants liabilities [Line Items]
Representative warrant liabilities, beginning balance	$ 62,222
Issuances/Assumptions			22,525
Change in fair value	(41,022)		(1,325)
Representative warrant liabilities, ending balance	$ 21,200		$ 21,200

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Net Loss Per Share Calculation (Details) - USD ($)	3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Schedule of Net Loss Per Share Calculation [Abstract]
Net loss	$ (2,959,426)	$ (126,475)	$ (144,111)	$ (4,083,109)	$ (580,983)	$ (707,458)	$ (598,593)
Weighted average shares outstanding (denominator for basic earnings per share)	16,688,945		15,130,393	16,588,940	15,130,393	1,044,861,360	1,044,861,360
Weighted average shares and assumed potential common shares (denominator for diluted earnings per share, treasury method)	16,688,945		15,130,393	16,588,940	15,130,393	1,044,861,360	1,044,861,360
Basic loss per share	$ (0.18)		$ (0.01)	$ (0.25)	$ (0.04)	$ 0	$ 0
Diluted loss per share	$ (0.18)		$ (0.01)	$ (0.25)	$ (0.04)	$ 0	$ 0

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Schedule of Common Share Equivalents are Excluded from the Calculation of Weighted Average Common Shares Outstanding (Details) - shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Schedule of Common Share Equivalents are Excluded from the Calculation of Weighted Average Common Shares Outstanding [Line Items]
Total potentially dilutive shares	12,030,000	12,030,000
Warrants [Member]
Schedule of Common Share Equivalents are Excluded from the Calculation of Weighted Average Common Shares Outstanding [Line Items]
Total potentially dilutive shares	12,030,000	12,030,000

Prepaid Expenses (Details)

Prepaid Expenses (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Prepaid Expenses [Abstract]
Prepaid expenses	$ 103,750	$ 3,840	$ 3,667

Intangible Assets (Details)

Intangible Assets (Details)									3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 27, 2024 USD ($)	Dec. 01, 2023 USD ($)	Mar. 05, 2023 USD ($)	Mar. 05, 2023 EUR (€)	Jan. 27, 2023 USD ($)	Dec. 15, 2022 USD ($)	Dec. 15, 2022 EUR (€)	Sep. 12, 2022 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Intangible Assets [Line Items]
Term fee	$ 10,000		$ 56,325	€ 50,000
Signing the agreement			112,650	100,000
Payment of license			$ 1,126,500	€ 1,000,000		$ 10,000	€ 10,000
Royalty percentage			2%	2%		3%	3%
Agreement paid									$ 0	$ 0	$ 0	$ 0
Purchase amount											1,308,270		$ 1,308,270
Payment fee	$ 50,000
Amount due											10,000
Acquired amount								$ 1,308,270
Royalty fees		$ 26,060									26,060		26,060
Professional fees									865,928	$ 117,770	1,634,790	$ 494,075	600,776	$ 526,007
Patent cost									48,420		48,420		48,420
Proprietary Pharmaceutical Drugs [Member]
Intangible Assets [Line Items]
Purchase amount					$ 10,000
Various Generic Drugs [Member]
Intangible Assets [Line Items]
Purchase amount											736,983		736,983
Four Generic Drugs [Member]
Intangible Assets [Line Items]
Purchase amount								$ 1,308,270
Needleless Syringe License [Member]
Intangible Assets [Line Items]
Purchase amount		$ 26,060
Patents [Member]
Intangible Assets [Line Items]
Purchase amount											48,420		48,420
Professional fees											30,898		47,740
Non-Exclusive License Agreement [Member]
Intangible Assets [Line Items]
Purchase amount			$ 56,325
Licensing Agreements [Member]
Intangible Assets [Line Items]
Agreement paid									$ 179,821		179,821		56,325
Purchase amount											$ 736,983		$ 736,983

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Intangible Assets [Line Items]
Total Licenses	$ 2,261,134	$ 2,137,638	$ 2,123,750
Patents	48,420	48,420	86,160
Total intangible assets	2,309,554	2,186,058	2,209,910
Non-Exclusive License Agreement [Member]
Schedule of Intangible Assets [Line Items]
Total Licenses	179,821	56,325
Proprietary pharmaceutical drugs [Member]
Schedule of Intangible Assets [Line Items]
Total Licenses	10,000	10,000
Various generic drugs [Member]
Schedule of Intangible Assets [Line Items]
Total Licenses	736,983	736,983	736,983
Four generic drugs (Encore) [Member]
Schedule of Intangible Assets [Line Items]
Total Licenses	1,308,270	1,308,270	1,386,766
Needleless Syringe License [Member]
Schedule of Intangible Assets [Line Items]
Total Licenses	$ 26,060	$ 26,060

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Accounts Payable and Accrued Expenses [Abstract]
Accounts payable and accrued expenses	$ 831,428	$ 153,719	$ 12,756

Notes Payable to Related Part_3

Notes Payable to Related Parties (Details) - USD ($)				1 Months Ended	9 Months Ended		12 Months Ended
	Dec. 12, 2023	Dec. 01, 2023	Dec. 31, 2022	Jan. 31, 2023	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Aug. 31, 2024	Jun. 30, 2024	May 31, 2024	Nov. 30, 2022
Notes Payable to Related Parties [Line Items]
Interest fee	$ 2,460				$ 2,460
Short-term loan												$ 300,000
Loan balance					0		$ 0
December 2023 [Member]
Notes Payable to Related Parties [Line Items]
Issued a promissory note					135,000
Notes payable to related parties						$ 135,000	135,000
August 2024 [Member]
Notes Payable to Related Parties [Line Items]
Issued a promissory note					80,000
Notes payable to related parties					80,000
December 2023 One [Member]
Notes Payable to Related Parties [Line Items]
Issued a promissory note					7,000	24,000
Notes payable to related parties					31,000	24,000	24,000			$ 31,000
Interest fee					2,460
August 2024 One [Member]
Notes Payable to Related Parties [Line Items]
Issued a promissory note					20,000
Notes payable to related parties					20,000
September 2024 [Member]
Notes Payable to Related Parties [Line Items]
Issued a promissory note					20,000
Notes payable to related parties					20,000
November 2022 [Member]
Notes Payable to Related Parties [Line Items]
Issued a promissory note								$ 300,000
Promissory Note [Member]
Notes Payable to Related Parties [Line Items]
Debt amount					20,000	135,000	135,000		$ 20,000
Promissory Note [Member] | December 2023 [Member]
Notes Payable to Related Parties [Line Items]
Issued a promissory note		$ 135,000
Debt amount		$ 135,000				13,500	13,500
Notes payable to related parties					$ 0	135,000	135,000
Promissory Note [Member] | August 2024 [Member]
Notes Payable to Related Parties [Line Items]
Debt amount						$ 24,000	24,000		$ 80,000		$ 7,000
Promissory Note [Member] | November 2022 [Member]
Notes Payable to Related Parties [Line Items]
Debt amount												300,000
Short-term loan												$ 300,000
Repaid amount			$ 50,000	$ 250,000
Loan balance							$ 0	$ 250,000

Notes Payable to Related Part_4

Notes Payable to Related Parties - Schedule of Notes Payable to Related Parties (Details) - USD ($)	Sep. 30, 2024	Jun. 30, 2024	Dec. 31, 2023
December 2023 [Member]
Notes Payable to Related Parties - Schedule of Notes Payable to Related Parties (Details) [Line Items]
Total notes payable to related parties			$ 135,000
May 2024 and December 2023 [Member]
Notes Payable to Related Parties - Schedule of Notes Payable to Related Parties (Details) [Line Items]
Total notes payable to related parties	$ 31,000	$ 31,000	24,000
August 2024 [Member]
Notes Payable to Related Parties - Schedule of Notes Payable to Related Parties (Details) [Line Items]
Total notes payable to related parties	80,000
August 2024 One [Member]
Notes Payable to Related Parties - Schedule of Notes Payable to Related Parties (Details) [Line Items]
Total notes payable to related parties	20,000
Septembert 2024 [Member]
Notes Payable to Related Parties - Schedule of Notes Payable to Related Parties (Details) [Line Items]
Total notes payable to related parties	20,000
Related Party [Member]
Notes Payable to Related Parties - Schedule of Notes Payable to Related Parties (Details) [Line Items]
Total notes payable to related parties	$ 151,000		$ 159,000

Notes Payable to Related Part_5

Notes Payable to Related Parties - Schedule of Notes Payable to Related Parties (Parentheticals) (Details) - USD ($)	9 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
December 2023 [Member]
Notes Payable to Related Parties - Schedule of Notes Payable to Related Parties (Parentheticals) (Details) [Line Items]
Original amount bearing no interest	$ 135,000
May 2024 and December 2023 [Member]
Notes Payable to Related Parties - Schedule of Notes Payable to Related Parties (Parentheticals) (Details) [Line Items]
Original amount bearing no interest	7,000	$ 24,000
original amount bearing a one-time interest fee	2,460
August 2024 [Member]
Notes Payable to Related Parties - Schedule of Notes Payable to Related Parties (Parentheticals) (Details) [Line Items]
Original amount bearing no interest	80,000
August 2024 One [Member]
Notes Payable to Related Parties - Schedule of Notes Payable to Related Parties (Parentheticals) (Details) [Line Items]
Original amount bearing no interest	20,000
Septembert 2024 [Member]
Notes Payable to Related Parties - Schedule of Notes Payable to Related Parties (Parentheticals) (Details) [Line Items]
Original amount bearing no interest	$ 20,000

Notes Payable (Details)

Notes Payable (Details) - USD ($)				9 Months Ended	12 Months Ended
	Apr. 22, 2024	Mar. 04, 2024	Sep. 12, 2022	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022	Oct. 02, 2024	Jun. 30, 2024	Dec. 12, 2023
Notes Payable [Line Items]
Issued promissory note					$ 1,308,270	$ 1,347,518
Aggregate purchase price	$ 2,000,000	$ 2,000,000
Aggregate of units (in Shares)	900,000	750,000
Transaction costs	$ 1,950,000	$ 1,950,000
Cash proceeds		181,339
Share issued (in Shares)				19,863,515	15,130,393	1,044,861,360
ANEW PIPE Financing Funds [Member]
Notes Payable [Line Items]
Cash proceeds				$ 50,000
Related Party [Member]
Notes Payable [Line Items]
Unpaid principal balance					$ 26,460
Series of Individually Immaterial Business Acquisitions [Member]
Notes Payable [Line Items]
Transaction costs	$ 1,000,000	$ 1,768,661
Promissory Note [Member]
Notes Payable [Line Items]
Issued promissory note			$ 1,308,270
Promissory note bore interest			6%	10%
Maturity date			Jun. 30, 2023
Interest fee					78,496
Unpaid principal balance				$ 0	1,308,270
Cash proceeds								$ 1,000,000
Convertible promissory notes				4,010,022
Convertible promissory notes total				3,950,000
Accrued interest				$ 60,022
Share issuance (in Shares)				4,050,617
Share issued (in Shares)				3,750,617			300,000
Interest payment			$ 6,541		78,496
Promissory Note [Member] | Related Party [Member]
Notes Payable [Line Items]
Issued promissory note									$ 24,000
Interest fee									$ 2,460
Previously Reported [Member]
Notes Payable [Line Items]
Issued promissory note					$ 1,332,270
Share issued (in Shares)					1,044,861,360
Previously Reported [Member] | Promissory Note [Member]
Notes Payable [Line Items]
Unpaid principal balance						$ 1,347,518

Related Parties (Details)

Related Parties (Details) - USD ($)					1 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2023	Dec. 12, 2023	Dec. 31, 2022	Oct. 10, 2021	Jan. 31, 2023	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022	Aug. 31, 2024	Dec. 01, 2023	Nov. 30, 2022	Sep. 12, 2022
Related Parties [Line Items]
Debt financing cost				$ 5,000,000
Earned amount							$ 240,000	$ 240,000
Owned amount	$ 80,000					$ 0	80,000
Short-term loan											$ 300,000
Shareholder repaid					$ 250,000			50,000
Loan balance						0	0
Interest fee		$ 2,460				2,460
Unpaid principal balance						20,000	0
Promissory note	1,308,270		$ 1,347,518				1,308,270	1,347,518
Promissory Note [Member]
Related Parties [Line Items]
Unpaid principal balance						80,000	0
Debt amount	135,000					20,000	135,000		$ 20,000
Promissory note												$ 1,308,270
Unpaid principal balance						0	1,308,270
Previously Reported [Member]
Related Parties [Line Items]
Promissory note	1,332,270						1,332,270
Previously Reported [Member] | Promissory Note [Member]
Related Parties [Line Items]
Unpaid principal balance								1,347,518
Minimum [Member]
Related Parties [Line Items]
Annual salary				240,000
Maximum [Member]
Related Parties [Line Items]
Annual salary				360,000
Related Party [Member]
Related Parties [Line Items]
Debt financing cost				5,000,000
Earned amount							240,000	240,000
Owned amount	80,000						80,000
Shareholder repaid					$ 250,000			50,000
Loan balance			250,000
Unpaid principal balance							135,000
Notes payable to related parties	159,000					151,000	159,000
Compensation amount							10,000
Consulting Fees							55,000
Promissory note		24,000
Unpaid principal balance							26,460
Related Party [Member] | Promissory Note [Member]
Related Parties [Line Items]
Debt amount		$ 2,460								$ 135,000
Related Party [Member] | Previously Reported [Member]
Related Parties [Line Items]
Loan balance	0
Notes payable to related parties	135,000						135,000
Related Party [Member] | Minimum [Member]
Related Parties [Line Items]
Annual salary				240,000
Related Party [Member] | Maximum [Member]
Related Parties [Line Items]
Annual salary				$ 360,000
Related Party [Member] | Promissory Note [Member]
Related Parties [Line Items]
Notes payable to related parties	$ 159,000						159,000
Short-Term Loan [Member] | Related Party [Member]
Related Parties [Line Items]
Short-term loan											$ 300,000
CEO [Member]
Related Parties [Line Items]
Unpaid principal balance						$ 31,000	$ 24,000

Stockholder's Equity (Details)

Stockholder's Equity (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024
Stockholder's Equity [Abstract]
Shares granted (in Shares)	3,144,000
Weighted average fair value (in Dollars per share)	$ 0.94
Stock-based compensation expense	$ 1,952,851	$ 1,990,366

Commitments and Contingencies (

Commitments and Contingencies (Details)									12 Months Ended
	Apr. 14, 2025 USD ($)	Feb. 12, 2025 USD ($)	Oct. 15, 2024 $ / shares	Sep. 24, 2024 USD ($) shares	Aug. 15, 2024 USD ($) shares	Jun. 21, 2024 USD ($)	Dec. 15, 2022 EUR (€)	Nov. 27, 2014 USD ($)	Dec. 31, 2022 USD ($)	Sep. 30, 2024 USD ($)	Sep. 19, 2024 $ / shares
Commitments and Contingencies [Line Items]
Renewal option								10 years
License agreement entitles								$ 100,000
Royalty payment, percentage								5%
Advisory fees						$ 3,000,000
Common shares for M&A advisory fee						0	€ 10,000
Deferred underwriting fees						0
Contract obligation						0				$ 0
Contract reset price per share (in Dollars per share) | $ / shares											$ 2
Common stock, value									$ 751,400
Dr. Robert Langer [Member]
Commitments and Contingencies [Line Items]
Annual base salary				$ 175,000
Number of shares received (in Shares) | shares				225,000
Consulting Agreements [Member]
Commitments and Contingencies [Line Items]
Contract obligation										$ 22,000
Subsequent Event [Member]
Commitments and Contingencies [Line Items]
Consecutive business days			30 years
Bid price per share (in Dollars per share) | $ / shares			$ 1
Chief Financial Officer [Member]
Commitments and Contingencies [Line Items]
Employment agreement term					3 years
Annual base salary					$ 325,000
Number of shares received (in Shares) | shares					200,000
Chief Financial Officer [Member] | Mr. LeBlanc [Member]
Commitments and Contingencies [Line Items]
Number of shares received (in Shares) | shares					100,000
Chief Operating Officer [Member]
Commitments and Contingencies [Line Items]
Employment agreement term					3 years
Annual base salary					$ 300,000
Number of shares received (in Shares) | shares					200,000
Chief Operating Officer [Member] | Peter Moriarty [Member]
Commitments and Contingencies [Line Items]
Number of shares received (in Shares) | shares					100,000
Common Stock [Member]
Commitments and Contingencies [Line Items]
Advisory fees						$ 1,500,000
Forecast [Member]
Commitments and Contingencies [Line Items]
Consecutive business days	10 days
Common stock, value	$ 1
Forecast [Member] | Publicly Held Shares [Member]
Commitments and Contingencies [Line Items]
Market value		$ 15,000,000
Consecutive business days		10 years
Forecast [Member] | Listed Securities [Member]
Commitments and Contingencies [Line Items]
Market value		$ 50,000,000
Consecutive business days		10 years
Reliance Industries Pvt Ltd [Member]
Commitments and Contingencies [Line Items]
Estimated acquisition price								$ 350,000

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)

3 Months Ended

9 Months Ended

Nov. 14, 2024

Nov. 11, 2024

Apr. 22, 2024

Mar. 31, 2024

Mar. 28, 2024

Mar. 27, 2024

Mar. 25, 2024

Mar. 15, 2024

Mar. 04, 2024

Mar. 01, 2024

Feb. 29, 2024

Jan. 19, 2024

Aug. 15, 2023

Sep. 12, 2022

Feb. 22, 2022

Feb. 01, 2022

Nov. 01, 2021

Sep. 30, 2024

Sep. 30, 2024

Sep. 30, 2023

Nov. 15, 2024

Dec. 31, 2023

Dec. 31, 2022

Subsequent Events [Line Items]

Exercise price of options period

3 years

Net amount

$ 1,000,000

Restricted common stock shares (in Shares)

1,000,000

Restricted common stock shares value

$ 25,000

Reverse stock split, description

1-for-2500

1-for-2500

1-for-2500

1-for-2500

Preferred stock, shares authorized (in Shares)

100,000,000

100,000,000

100,000,000

Preferred stock shares, par value (in Dollars per share)

$ 0.0001

$ 0.0001

$ 0.0001

Preferred stock, shares sold (in Shares)

100,000

2,000,000

1,666,667

Preferred stock, shares value

Preferred stock shares, granted (in Shares)

0

0

0

Equity compensation of unregistered shares

$ 1,952,851

Dr. Sinkule [Member]

Subsequent Events [Line Items]

Options shares (in Shares)

1,000,000

Dr. Sinkule [Member]

Subsequent Events [Line Items]

Base salary

$ 360,000

Investor [Member] | Convertible Promissory Note [Member]

Subsequent Events [Line Items]

Convertible discount, percentage

10%

Convertible promissory note

$ 700,000

Maturity term

24 months

Interest rate paid in cash per annum

10%

Weighted average interest rate

15%

Investor [Member] | Redwoods Acquisition Corp [Member] | Convertible Promissory Note [Member]

Subsequent Events [Line Items]

Acquisition price per share (in Dollars per share)

$ 9

Management Consulting Services Agreement [Member]

Subsequent Events [Line Items]

Reverse stock split, description

1-for-2500

Subsequent Event [Member]

Subsequent Events [Line Items]

Annual compensation amount

$ 36,000

Subscription received

$ 100,000

Restricted common stock shares (in Shares)

200,000

Restricted common stock shares value

$ 50,000

Price per share (in Dollars per share)

$ 0.0067

$ 0.006

$ 0.0044

$ 0.25

Unregistered shares issued for services (in Shares)

9,900,000

Reverse stock split, description

1-for-2500

1-for-2500

Reverse stock split shares, value

$ 6,700

$ 12,000

$ 43,560

Warrants to purchase shares (in Shares)

1,500,000

Warrants exercise price (in Dollars per share)

$ 2.5

Warrants expires

Mar. 04, 2027

Call option granted (in Shares)

1,000,000

2,000,000

Call Option expires

Mar. 15, 2029

Equity compensation of unregistered shares

$ 50,000

$ 10,000

Cash payment

$ 50,000

Authorized but unissued shares (in Shares)

50,000

Convertible promissory note

$ 1,300,000

Subsequent Event [Member] | Convertible Promissory Note [Member]

Subsequent Events [Line Items]

Convertible promissory note

$ 1,200,000

Convertible discount, percentage

20%

Net amount

$ 1,000,000

Subsequent Event [Member] | Convertible Promissory Note [Member]

Subsequent Events [Line Items]

Convertible discount, percentage

10%

Maturity term

24 months

Interest rate paid in cash per annum

10%

Weighted average interest rate

15%

Subsequent Event [Member] | Management Consulting Services Agreement [Member]

Subsequent Events [Line Items]

Acquisition price per share (in Dollars per share)

$ 10

Subsequent Event [Member] | Redwoods Acquisition Corp [Member]

Subsequent Events [Line Items]

Acquisition price per share (in Dollars per share)

$ 9

Subsequent Event [Member] | Call Option [Member]

Subsequent Events [Line Items]

Call option granted (in Shares)

3,000,000

Subsequent Event [Member] | Management Consulting Services Agreement [Member]

Subsequent Events [Line Items]

Price per share (in Dollars per share)

$ 0.006

Reverse stock split shares, value

$ 6,000

Call option granted (in Shares)

1,000,000

Subsequent Event [Member] | Management Consulting Services Agreement [Member] | Call Option [Member]

Subsequent Events [Line Items]

Call Option expires

Mar. 15, 2029

Individuals [Member] | Subsequent Event [Member]

Subsequent Events [Line Items]

Shares granted (in Shares)

3

Executives [Member] | Subsequent Event [Member]

Subsequent Events [Line Items]

Shares granted (in Shares)

2

University [Member] | Subsequent Event [Member] | Management Consulting Services Agreement [Member]

Subsequent Events [Line Items]

Acquisition price per share (in Dollars per share)

$ 20

Series D Preferred Stock [Member] | Subsequent Event [Member]

Subsequent Events [Line Items]

Preferred stock, shares authorized (in Shares)

160,000

Preferred stock shares, par value (in Dollars per share)

$ 2.5

$ 0.001

Cash dividend at annual rate

6%

Preferred stock, shares sold (in Shares)

50,000

Preferred stock, shares value

$ 125,000

Preferred stock shares, granted (in Shares)

100,000

Series B Preferred Stock [Member]

Subsequent Events [Line Items]

Preferred stock, shares authorized (in Shares)

500,000

500,000

Preferred stock shares, par value (in Dollars per share)

$ 0.001

$ 0.001

Preferred stock, shares value

$ 405

Preferred stock shares, granted (in Shares)

405,250

Series B Preferred Stock [Member] | Subsequent Event [Member]

Subsequent Events [Line Items]

Preferred stock shares, granted (in Shares)

30,000

Shares cancelled (in Shares)

30,000

Common Stock [Member] | Subsequent Event [Member]

Subsequent Events [Line Items]

Price per share (in Dollars per share)

$ 0.006

Reverse stock split, description

1-for-2500

Reverse stock split shares, value

$ 18,000

Common Stock [Member] | Subsequent Event [Member] | Management Consulting Services Agreement [Member]

Subsequent Events [Line Items]

Acquisition price per share (in Dollars per share)

$ 30

Forecast [Member] | Convertible Promissory Note [Member]

Subsequent Events [Line Items]

Convertible discount, percentage

10%

Convertible promissory note

$ 2,000,000

Interest rate paid in cash per annum

10%

Weighted average interest rate

15%

Forecast [Member] | Redwoods Acquisition Corp [Member] | Convertible Promissory Note [Member]

Subsequent Events [Line Items]

Acquisition price per share (in Dollars per share)

$ 9

Intangible Assets - Schedule _2

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Intangible Assets [Line Items]
Total Licenses	$ 2,261,134	$ 2,137,638	$ 2,123,750
Patents	48,420	48,420	86,160
Total intangible assets	2,309,554	2,186,058	2,209,910
Non-Exclusive License Agreement [Member]
Schedule of Intangible Assets [Line Items]
Total Licenses	179,821	56,325
Proprietary pharmaceutical drugs [Member]
Schedule of Intangible Assets [Line Items]
Total Licenses	10,000	10,000
Various generic drugs [Member]
Schedule of Intangible Assets [Line Items]
Total Licenses	736,983	736,983	736,983
Four generic drugs (Encore) [Member]
Schedule of Intangible Assets [Line Items]
Total Licenses	1,308,270	1,308,270	1,386,766
Needleless Syringe License [Member]
Schedule of Intangible Assets [Line Items]
Total Licenses	$ 26,060	$ 26,060

Notes Payable to Related Part_6

Notes Payable to Related Parties - Schedule of Notes Payable to Related Parties (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
November 2022 [Member]
Schedule of Notes Payable to Related Parties [Line Items]
Total notes payable to related parties		$ 250,000
December 2023 [Member]
Schedule of Notes Payable to Related Parties [Line Items]
Total notes payable to related parties
Related Party [Member]
Schedule of Notes Payable to Related Parties [Line Items]
Total notes payable to related parties		$ 250,000
Previously Reported [Member] | November 2022 [Member]
Schedule of Notes Payable to Related Parties [Line Items]
Total notes payable to related parties
Previously Reported [Member] | December 2023 [Member]
Schedule of Notes Payable to Related Parties [Line Items]
Total notes payable to related parties	135,000
Previously Reported [Member] | Related Party [Member]
Schedule of Notes Payable to Related Parties [Line Items]
Total notes payable to related parties	$ 135,000

Notes Payable to Related Part_7

Notes Payable to Related Parties - Schedule of Notes Payable to Related Parties (Parentheticals) (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
November 2022 [Member]
Schedule of Notes Payable to Related Parties [Line Items]
Original amount bearing no interest			$ 300,000
December 2023 [Member]
Schedule of Notes Payable to Related Parties [Line Items]
Original amount bearing no interest	$ 135,000
Previously Reported [Member] | November 2022 [Member]
Schedule of Notes Payable to Related Parties [Line Items]
Original amount bearing no interest		$ 300,000
Previously Reported [Member] | December 2023 [Member]
Schedule of Notes Payable to Related Parties [Line Items]
Original amount bearing no interest		$ 135,000

Equity Transactions (Details)

Equity Transactions (Details) - USD ($)	Aug. 15, 2023	Sep. 12, 2022	Feb. 22, 2022	Feb. 01, 2022	Nov. 01, 2021	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Equity Transactions [Line Items]
Common stock, shares authorized						1,000,000,000	1,000,000,000	1,500,000,000
Common stock, par value (in Dollars per share)						$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized						100,000,000	100,000,000
Preferred stock, par value (in Dollars per share)						$ 0.0001	$ 0.0001
Common stock, shares issued						19,863,515	15,130,393	1,044,861,360
Common stock, shares outstanding						19,863,515	15,130,393	1,044,861,360
Preferred stock, shares issued						0	0
Preferred stock, shares outstanding						0	0
Reverse split	1-for-2500	1-for-2500		1-for-2500	1-for-2500
Stock purchase	100,000	2,000,000		1,666,667
Common stock, value (in Dollars)		$ 500,000		$ 250,000		$ 1,986	$ 1,513	$ 104,486
Restricted common stock			1,000,000
Restricted common stock (in Dollars)	$ 25,000
Restricted common stock per value (in Dollars per share)	$ 0.25
Series B Preferred Stock [Member]
Equity Transactions [Line Items]
Preferred stock, shares authorized							500,000	500,000
Preferred stock, par value (in Dollars per share)							$ 0.001	$ 0.001
Preferred stock, shares issued								405,250
Preferred stock, shares outstanding								405,250
Series C Preferred Stock [Member]
Equity Transactions [Line Items]
Preferred stock, shares authorized							5,000,000	5,000,000
Preferred stock, par value (in Dollars per share)							$ 0.0001	$ 0.0001
Preferred stock, shares issued							1,000,000	1,000,000
Preferred stock, shares outstanding							1,000,000	1,000,000
Preferred Class B [Member]
Equity Transactions [Line Items]
Preferred stock, shares issued							405,250	405,250
Preferred stock, shares outstanding							405,250	405,250
Common Stock [Member]
Equity Transactions [Line Items]
Common stock, shares authorized							1,500,000,000
Common stock, par value (in Dollars per share)		$ 0.25	$ 0.0014	$ 0.15			$ 0.0001
Common Stock [Member] | Preferred Class B [Member]
Equity Transactions [Line Items]
Common stock, shares issued							1,044,861,360	1,044,861,360
Common stock, shares outstanding							1,044,861,360	1,044,861,360
Restricted Common Stock [Member]
Equity Transactions [Line Items]
Reverse split	1-for-2500
Stock purchase	300,000
Restricted common stock (in Dollars)	$ 75,000
Restricted common stock per value (in Dollars per share)	$ 0.25

Material Contracts (Details)

Material Contracts (Details)

3 Months Ended

12 Months Ended

Jun. 21, 2024 USD ($)

Mar. 01, 2023 USD ($)

Feb. 28, 2023 USD ($)

Jan. 31, 2023 USD ($)

Dec. 15, 2022 EUR (€)

May 01, 2022 USD ($)

Nov. 19, 2021

Nov. 27, 2014 USD ($)

Jul. 31, 2022 USD ($)

Dec. 31, 2023 USD ($) $ / shares shares

Sep. 30, 2024 USD ($) $ / shares

Dec. 31, 2022 USD ($) $ / shares

Sep. 12, 2022 USD ($) $ / shares

Feb. 22, 2022 $ / shares

Feb. 01, 2022 USD ($) $ / shares

Material Contracts (Details) [Line Items]

Renewal option

10 years

Company to pay

$ 100,000

Royalty payment percentage

5%

Net proceeds

3%

Percentage of commission fee

5%

License fee (in Euro)

$ 0

€ 10,000

Net sales

3%

3%

Compensated amount

$ 10,000

$ 15,000

Common stock value

$ 1,513

$ 1,986

$ 104,486

$ 500,000

$ 250,000

Common stock per share (in Dollars per share) | $ / shares

$ 0.0001

$ 0.0001

$ 0.0001

Description of markets advisory agreement

Upon consummation of a transaction, the Company will pay the firm an M&A fee consisting of an aggregate of a sum equal to the greater of $2,500,000 or the sum of the following amounts:   ● four percent (4.0%) of the first $100 MM of Aggregate Value;   ● three percent (3.0%) of any amount of the Aggregate Value between $100 MM and $200 MM;   ● two percent (2.0%) of any amount of the Aggregate Value between $200 MM and $300MM;   ● one percent (1.0%) of any amount of the Aggregate Value exceeding $300 MM  In addition, the Company will pay the firm a financing fee of seven percent (7%) of the aggregate amount of proceeds received from investors in the financing of any equity or equity-linked securities and three percent (3%) of the aggregate amount of proceeds received from the Financing of any non-equity-linked debt securities and credit facilities. As of December 31, 2023, the Company owes $-0- under the agreement

Transaction fees

$ 2,500,000

Consultant fee

$ 2,500

$ 2,500

$ 2,500

$ 10,000

Aggregate amount

$ 12,500

Management Consulting Services Agreement [Member]

Material Contracts (Details) [Line Items]

Equity compensation

3%

Common Stock [Member] | Business Development and Consulting Agreement [Member]

Material Contracts (Details) [Line Items]

Common stock value

$ 1,400

Common stock per share (in Dollars per share) | $ / shares

$ 0.0014

Common Stock [Member]

Material Contracts (Details) [Line Items]

Shares of common stock (in Shares) | shares

41,376,400

Common stock per share (in Dollars per share) | $ / shares

$ 0.0001

$ 0.25

$ 0.0014

$ 0.15

Common Stock [Member] | Business Development and Consulting Agreement [Member]

Material Contracts (Details) [Line Items]

Shares of common stock (in Shares) | shares

1,000,000

Reliance Industries Pvt Ltd [Member]

Material Contracts (Details) [Line Items]

Estimated acquisition price

$ 350,000

Income Taxes (Details)

Income Taxes (Details)	12 Months Ended
	Dec. 31, 2022 USD ($)
Income Taxes [Abstract]
Change in the valuation allowance	$ 423,224

Income Taxes - Schedule of Stat

Income Taxes - Schedule of Statutory Federal Income Tax Rate to Income Before Provision for Income Taxes (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Statutory Federal Income Tax Rate to Income Before Provision for Income Taxes [Abstract]
Income tax provision at the federal statutory rate	28%	21%
Effect on operating losses	(28.00%)	(21.00%)

Income Taxes - Schedule of Net

Income Taxes - Schedule of Net Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Schedule of Net Deferred Tax Assets [Abstract]
Deferred tax asset	$ 1,098,630	$ 675,406
Valuation allowance	(10,968,630)	(675,406)
Net deferred tax asset